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ABSTRACT
Melanoma is a lethal malignancy with limited treatment options for advanced
metastatic stages. New targeted therapeutic options with discovery of BRAF and MEK
inhibitors have shown significant survival benefit. Despite the recent progress, inefficient
tumor accumulation and dose limiting systemic toxicity remains pressing challenges for
treating metastatic melanoma and there is a need for drug delivery approach to improve
therapeutic index of chemotherapeutics. Nanoparticle based drug delivery represents
promising approach to enhance efficacy and reduce the dose limiting systemic toxicity.
Nanoparticles can be formulated either by physical encapsulation of drugs or by
covalent conjugation of drugs to the polymeric backbone. Nanoparticles based
strategies for encapsulation and conjugation of drugs to the polymer was reviewed in
Chapter 2 where we summarized non-covalent interactions between polymer backbone
and drug for physical encapsulation, various polymeric backbones for drug conjugation
and application of photodynamic therapy in melanoma.
Phototherapy, a light activated treatment modality is a potential therapeutic option
for treatment of melanoma. Excitation of photosensitizer by light of specific wavelength
can be clinically utilized for fluorescence assisted tumor surgery, photoacoustic imaging,
photochemical internalization and phototherapy. Indocyanine green, water soluble FDA
approved anionic tricarbocyanine with excellent safety profile and absorption in the near
infrared (NIR) range is an excellent photosensitizer. However, short half-life (2-4
minutes) and limited extravascular distribution restricts PT application of ICG. In chapter
3, we have described ICG based phototherapy wherein plasma circulation and tumor
accumulation of ICG was improved by designing its micelles formulation. ICG micelles

were formulated by covalently conjugating ICG-NH2 to the pendant carboxyl groups of
poly (ethylene glycol)-block-poly(2- methyl-2-carboxyl-propylene carbonate)

(PEG-

PCC) copolymer using carbodiimide coupling. ICG conjugated amphiphillic polymer selfassembled into micelles with particle size of 30-50 nm and high drug loading. These
ICG conjugated micelles exhibited significant in vitro photodynamic cytotoxicity. Use of
sodium azide and NIR radiation at 4° C revealed photodynamic and photothermal as
primary mechanism of cytotoxicity of ICG solution and ICG conjugated micelles
respectively. In vivo NIR imaging demonstrated ICG conjugated micelles prolonged ICG
circulation and increased its tumor accumulation through enhanced permeability and
retention effect Increase in tumor accumulation improved therapeutic efficacy with
complete tumor regression in NIR irradiated ICG conjugated micelles compared to free
ICG and control in A375 human melanoma tumor model in athymic nude mice. These
results suggest that ICG conjugated micelles can be potentially utilized for
phototherapy.
Clinical translation of tubulin inhibitors for treating melanoma is limited by multidrug
efflux transporters, poor aqueous solubility, and dose-limiting peripheral toxicities.
Tubulin inhibitors with efficacy in taxane-resistant cancers are promising drug
candidates and can be used as single agent or in conjunction with other chemotherapy.
In chapter 4, we describe synthesis of tubulin inhibitors with activity in taxane resistant
cell lines with IC50 in nanomolar range for the treatment of metastatic melanoma.
LY293, a 5 indole derivative analog, binds to colchicine binding site and does not exhibit
clinically prevalent drug resistance mechanism such as multidrug resistance (MDR)
protein, breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp).

Since

LY293 is poorly soluble in water, LY293 was formulated as polymeric nanoparticles for
systemic therapy of melanoma. Methoxy polyethylene glycol-b-poly (carbonate-colactide) (mPEG-b-P (CB-co-LA)) random copolymer was synthesized and characterized
by 1H NMR and gel permeation chromatography (GPC). Polymeric nanoparticles were
formulated using o/w emulsification method with a mean particle size of 150 nm and
loading efficiency of 7.40%. Treatment with LY293 loaded nanoparticles effectively
inhibited the proliferation of melanoma cells in vitro and exhibited concentration
dependent cell cycle arrest in G2/M phase. In vivo, LY293 loaded nanoparticles
significantly inhibited the proliferation of highly aggressive metastasized melanoma in a
syngeneic lung metastasis melanoma mouse model without toxicity to vital organs.
Islet transplantation has been performed in many patients especially undergoing
kidney transplantation to treat Type I diabetes. Proportion of recipients who achieved
insulin independence is low and is limited by long-term graft rejection and by primary
non-function of islets. Primary non-function is characterized as the loss of islet viability
and function caused by non-immune reasons, such as the disruption of islet
microvasculature and apoptosis of islets due to production of inflammatory cytokines at
the transplantation sites. In chapter 5, we studied the potential of human bone marrow
derived mesenchymal stem cells (hBMSCs) as gene carriers for improving the outcome
of human islet transplantation. hBMSCs were transduced with Adv-hVEGF-hIL-1Ra to
overexpress human vascular endothelial growth factor (hVEGF) and human interleukin1 receptor antagonist (hIL-1Ra). Viability of human islets co-cultured with hBMSCs was
determined

by

membrane

fluorescent

method

and

glucose

stimulation

test.

Transduced hBMSCs and human islets were co-transplanted under the kidney capsule

of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ diabetic mice and blood glucose levels were
measured over time to evaluate the efficacy of genetically modified hBMSCs. Our in
vitro and in vivo results showed hBMSCs can be used as gene delivery vehicles to
improve the outcome of islet transplantation without affecting their stemness and
differentiation potential.
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CHAPTER 1 INTRODUCTION
1.1 Polymeric nanocarriers for treatment of melanoma
Melanoma is an extremely aggressive type of skin cancer with a high potential of
metastasis and ability to develop resistance to most anticancer agents. While surgery
and radiation are the first line therapy for treating localized melanoma, systemic therapy
is the cornerstone of clinical management of metastatic melanoma (1). Currently
dacarbazine (DTIC) and kinase inhibitors are the Food and Drug Administration (FDA)
approved drugs for the treatment of metastatic melanoma with modest efficacy and
development of resistance (2-4). Tubulin inhibitors like vinca alkaloids and taxanes such
as paclitaxel have been clinically prescribed as a single agent or in combination with
other chemotherapeutic agents but efficacy are limited by development of resistance
(5). Tubulin polymerization inhibitors with antiproliferative IC50 in nanomolar range and
ability to circumvent multidrug resistance (MDR) protein, breast cancer resistance
protein (BCRP) and P-glycoprotein (P-gp) was synthesized by our collaborator (6).
However, poor aqueous solubility of

(2-(1H-Indol-5-yl) thiazol-4-yl) 3, 4, 5-

trimethoxyphenyl methanone (LY293) necessitates the use of cosolvent for its systemic
delivery. Biodegradable polymeric nanoparticles are attractive formulation strategies for
solubilizing the hydrophobic drug within their core and modulate the drug release. In
chapter 3, we have synthesized and characterized a biodegradable amphiphillic
polymer for nanoparticulate formulation of poorly soluble drug LY293: We carried out
the proposed work with the following aims:

1



Design and optimize synthesis of methoxypoly(ethylene glycol) -b- poly
(carbonate-co-lactide) [mPEG-b-P (CB-co-LA)] and perform its characterization
by 1H NMR and GPC



Perform formulation and characterization of LY293 loaded nanoparticles.



Determine the in-vitro

anticancer efficacy, apoptosis and study of cell cycle

perturbation by LY293


Determine the in-vivo anticancer efficacy of nanoparticulate formulation of LY293
in lung metastatic melanoma mouse model after systemic administration.
In chapter 4, we have designed polymeric micelles of indocyanine green for

phototherapy (PT) of melanoma. Phototherapy (PT), a combination of photodynamic
therapy (PDT) and photothermal therapy (PTT) involves the administration of
biocompatible photosensitizer followed by its excitation with light of specific
wavelength which leads to generation of local heat and reactive oxygen species.
The major advantage of PT is that both photosensitizer and irradiating light are inert
by themselves and do not cause any systemic toxicity or collateral damage.
However, application of indocyanine green is limited by its short plasma circulation
half-life and inefficient tumor accumulation for phototherapy.

To improve the

plasma circulation and thereby, enhance the tumor accumulation, we formulated and
characterized micelles formulation of indocyanine green. We performed the work
with the following aims:


Synthesis and characterization of mPEG-b-PCC-g-indocyanine green -gdodecanol (mPEG-PCC-g- NH2 ICG -g-DC)



Formulation and characterization of ICG conjugated polymeric micelles
2



Perform cellular uptake and in vitro phototoxicity with elucidation of mechanism
of cytotoxicity



Determine in vivo biodistribution using near infrared fluorescence imaging and invivo photodynamic toxicity

1.2 hBMSCs as gene delivery vehicles to express VEGF and IL-1Ra to improve the
outcome of human islet transplantation
The main objective of this work was to study genetic modification of human bone
marrow derived mesenchymal stem cells for improving the outcome of islet transplant.
We have previously shown that genetic modification of human islet with growth factors
and cytokines receptor antagonist improved the outcome of islet transplant (7, 8).
However, transduction of islets with virus results in immune response especially when
relatively higher multiplicity of infection (MOI) is used to get desired transgene
expression (9).
To resolve this potential issue, we hypothesized that hBMSCs can be genetically
modified by adenovirus for transgene expression and their use as gene delivery
vehicles. In addition, hBMSCs also provide immune protection to islet grafts and
improve the function and survival of grafted islet by secreting various growth factors. We
carried out the proposed aim:


Perform hBMSCs characterization, adenovirus transduction and quantification of
transgene expression.



Determine the effect of genetically modified BMSCs on islet viability and islet
function in vitro.



Determine the in vivo outcome of co-transplantation of genetic modified BMSCS
and islet transplant in diabetic NSG mice.
3

CHAPTER 2 NANOPARTICLES MEDIATED DRUG DELIVERY FOR TREATING
MELANOMA*
2.1 Introduction
Melanoma is the cancer of melanocytes which are present as single cells within the
basal layer of epidermis. Melanoma is a highly aggressive skin cancer with potential of
metastasis and responsible for majority of skin related deaths. The 5-year survival of
metastasized melanoma is around 10 % (10). Systemic chemotherapy is mainstay for
the treatment of melanoma and DTIC was standard of care for melanoma till the
approval of new targeted kinase inhibitors. DTIC monotherapy is associated with a poor
response rate of around 7.2-7.5 % and does not extend survival benefits (11).
About 60% of melanoma patients carry activating mutations in the gene encoding
the serine–threonine protein kinase B-RAF (BRAF). Discovery of these activating
mutations paved the way for development of small molecule inhibitors targeting
mitogen-activated protein (MAP) kinase pathway.

BRAF inhibitors (vemurafenib,

dabrafenib), MEK inhibitor (trametinib), and the combination of dabrafenib with
trametinib are the newest small molecules approved by the FDA approved for treating
BRAF mutated melanoma. However, response to potent BRAF inhibitors is short lived
and disease progression is seen at a median of 5-7 months (3, 12). Hence, there is a
need for improved treatment options for effective treatment of melanoma. Tubulin
binding agents (TBA), platinum analogues, anthracyclines and nitrosoureas have been
clinically prescribed in melanoma as combination therapy (1) and exhibits comparable
response rate to DTIC.
*Adapted with permission. Mundra V, Li W, Mahato RI. Nanoparticle-mediated drug
delivery for treating melanoma. Nanomedicine (Lond). 2015;10(16):2613-33
4

However, multiple drug resistance (MDR) mechanisms, poor delivery and dose
limiting systemic toxicity restrict the therapeutic application of these chemotherapeutic
drugs. Thus, there is a need to improve the biodistribution of chemotherapeutics to
tumor with minimum peripheral exposure and thereby minimize the systemic toxicity.
Advent of nanoparticle based drug delivery resulted in tumor selective delivery of drugs
by enhanced permeability and retention effect (EPR) with reduced peripheral exposure.
Furthermore, interaction between receptors overexpressed by tumor and their ligands
has been exploited to enhance the cellular uptake of nanoparticles. However,
formulation of nanoparticles with enhanced stability in plasma and limited premature
drug release are potential pitfalls in harnessing the improved biodistribution by EPR
effect. Hence, we have reviewed the different polymer modifications to enhance the
non-covalent interaction between polymer backbone and drug as well as polymer drug
conjugates to design kinetically stable nanoparticles with enhanced drug loadings. In
addition, nanoparticles based photodynamic therapy (PDT) presents exciting avenues
for detection, treatment and evasion from possible mechanism of resistance from
melanoma.

In this chapter, we summarize the different polymer modification for

preparation of nanoparticles, nanoparticles for PDT and targeted nanocarriers followed
by conclusion and future outlook of nanoparticle based therapy for melanoma.
2.2 Drugs acting on tubulin polymerization
Microtubules are dynamic cytoskeleton structure in eukaryotic cells and play a key
role in maintaining the cellular structure, transport of vesicles, cell signaling and mitosis
(13). Microtubules are long, slender, filamentous, cylindrical tubes which are composed
of α-tubulin and β- tubulin heterodimer. Microtubules results from polymerization of αβ
tubulin heterodimer in two steps; nucleation and elongation. During nucleation, an
5

oligomer consisting of 6-12 αβ tubulin heterodimer units is formed. Reversible, noncovalent addition of αβ tubulin heterodimer to oligomer during elongation leads to the
formation of protofilament. Polymerization of microtubules is dynamic process and
hydrolysis of tubulin bound GTP provides energy. Microtubules essentially exhibit two
different dynamic behavior, “treadmilling” and “dynamic instability”. Treadmilling refers
to the net addition of tubulin subunit to the plus end along with the net dissociation of
subunit from the minus end without affecting the length of microtubules. Dynamic
instability is characterized by alternate switch between phases of growth and
shortening. One end of microtubules, plus end shows rapid and prominent growth and
shortening as compared to the minus end (14). This rapid and prominent microtubule
dynamics is essential for successful cell mitosis. Microtubules undergo extensive
reorganization where plus end of microtubules binds kinetochores of chromosomes and
arrangement of microtubules of metaphase plate. Oscillation of chromosomes at the
metaphase plate and shortening of microtubules spindles leads to separation of the
chromosomes and cell mitosis (15).
Crucial role played by microtubules in the cell mitosis makes them an ideal target for
arresting rapid proliferating cancer cells and inducing apoptosis.

Drugs acting on

dynamics of polymerization are also known as antimitotic as these agents not only
perturb mitosis but also arrest proliferating cancer cells during interphase. These
microtubule targeting drugs can be classified as depolymerizing or polymerizing agents
based on their action on assembly of microtubules. Antimitotic agents exert their effect
by binding either to the αβ tubulin heterodimer subunit or by binding to the microtubule
assembly. Majority of microtubules acting drugs were initially isolated from natural

6

products and paved the way for further development of microtubule acting agents.
These agents interact with microtubules through at least four known sites; the
laulimalide, taxane, vinca alkaloid and colchicine site (16). Vinca alkaloids were the first
microtubule agents which were isolated from periwinkle leaves and arrest mitosis at
metaphase. Vincristine, vinblastine and vinorelbine bind to the tubulin molecules at the
growing tip of microtubules and thereby promote depolymerization of microtubules. At
higher concentrations, vinca alkaloids also interact at the interface of two αβ tubulin
heterodimer and prevent self-association of αβ tubulin subunits. Laulimalide,
microtubule stabilizing agent have been isolated from marine sponge and show
excellent cytotoxicity in vitro. Laulimalide binds to different site than PTX and stabilize
microtubule. Laulimalide retains its activity in PTX resistant cell lines and P-gp over
expressing cell lines. However, poor efficacy to toxicity ratio limited its therapeutic value
(14). Taxanes bind to polymerized microtubule at β subunit and prevent the
depolymerization of microtubules. Colchicine is isolated from Colchicum autumnale L
and is used as monotherapy to treat familial Mediterranean fever and acute gout flares.
Colchicine binds to the β-tubulin and gets polymerized into tubulin heterodimer. This
high affinity binding of colchicine alters the straight structure of tubulin dimer to the
curved structure and thereby destabilizing the microtubules. However, low therapeutic
index of colchicine limits its clinical translation.
Successful chemical synthesis and clinical translation of taxanes and vinca alkaloids
has made colchicine binding site as a promising site to target cancer cells. Several
colchicine binding agents have been synthesized but no agent has been yet approved
for

clinical

use.

Our

group

has

synthesized

7

a

series

of

4-substituted

methoxybenzoylaryl- thiazoles (SMART) compounds with structural modification of lead
compound, substituted 2-aryl-thiazolidine-4-carboxylic acid amides (ATCAA) (Figure
2.1). SMART compounds exhibited nanomolar efficacy against melanoma with activity
against Pgp overexpressing cell lines and better toxicity profile compared to existing
depolymerizing agent (17-19). These derivatives were synthesized with emphasis on
structure-activity relationship (SAR) studies for the central thiazolidine ring of the
ATCAA analogs, the effect of spacers, and to remove the chiral centers. Among the
synthesized derivatives, SMART compounds containing hydrophobic thiazole ring have
extremely poor water solubility which requires use of surfactants for effective dosing. In
addition, thiazole ring of the SMART compounds may undergo oxidative cleavage
resulting in a nitroxide and ultimately reduced in vivo stability for SMART analogs.
Biomimetic replacement of the central thiazole ring of the SMART compounds with
imidazole moiety was performed to design 2-aryl-4-benzoyl-imidazole (ABI) analogs.
Imidazole moiety was introduced as imidazole is present in many existing drugs and
has been proven to be very stable. Secondly, compared with the thiazole ring, the
imidazole ring is much more hydrophilic, is expected to have improved aqueous
solubility which would its systemic administration without toxicity. Preformulation and
preclinical characterization confirmed this where compared to SMART; ABI analogs
have

higher

water solubility,

improved

pharmacokinetic properties,

and

oral

bioavailability without compromising activity (20). To further improve the aqueous
solubility of thiazole derivatives, phenyl thiazole (PAT) analogue having an amino
linkage were synthesized (Figure 2.1) (6, 20). PAT analogues exhibited nanomolar
efficacy against melanoma and improved bioavailability as compared to SMART
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analogues. Therapeutic potential of these synthesized ABI and SMART analogues can
be further potentiated by minimizing the systemic side effects and improving their
delivery to tumor.

9

Figure 2-1. Structure Activity Relationship of 4-substituted methoxybenzoylaryl
thiazoles compound on efficacy and oral bioavailability
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2.3 Nanotechnology for Drug Delivery
Lack of selectivity for tumor tissue, unfavorable physicochemical property and poor
biopharmaceutical characteristics limit the therapeutic efficacy of anticancer drugs. Free
drugs circulate throughout the body and permeate the cell membrane through passive
diffusion. This non-selective distribution and cellular permeability of anticancer drugs is
the primary reason for dose limiting toxicity (21, 22). Poor physicochemical and
biopharmaceutical properties of anticancer drugs present additional challenges in their
delivery. Drugs with low water solubility require cosolvent for their administration and
causes systemic toxicity, whereas water soluble drugs are rapidly eliminated through
kidney restricting the plasma residence time for their partition to tumor.
Nanotechnology has provided a platform to overcome these challenges and deliver
drugs smartly to tumor (23, 24). Doxil and Abraxane are the two clinically approved
nanoproducts of DOX and PTX with improved biodistribution and safety profiles,
respectively.

Micelles,

nanoparticles,

liposomes,

dendrimers and polymer-drug

conjugates are the most commonly used nanoparticles for drug delivery. Drugs delivery
by nanoparticles exhibit altered biodistribution and pharmacokinetic profiles. Maeda et
al. first have shown macromolecules preferentially accumulate at the tumor site due to
enhanced vascular permeability and poor lymphatic drainage (25, 26). High molecular
weight polymers (> 50 kDa) showed significant accumulation at 6 h while low molecular
weight polymers cleared rapidly due to rapid diffusion into the blood stream. Prolonged
circulation of nanoparticles improves their accumulation at the tumor site for local
release of drug and/or uptake of drug loaded nanoparticles by cancer cells. To
maximize the drug delivery, it is imperative that drug release rate constant (Kr) while
nanoparticles are in the circulation should be miniscule as compared to distribution rate
11

constant of nanoparticles to tumor (Kd) (Figure 2.2). Premature release of drugs from
the nanoparticles would nullify the advantage of EPR effect and biodistribution of
nanoparticles associated drug would be identical to that of the free drug. However,
drugs associated with the nanoparticles are pharmacologically inactive and requires
drug release at the tumor site to show therapeutic effect. Considering this, the
nanoparticles should be designed to allow effective accumulation of its payload at the
tumor site but should be released quick enough to maintain the concentration of free
drug above the IC50 values. Broadly, drugs are either encapsulated within the
nanoparticles or conjugated to a lipid or polymeric nanoparticles. In the following
sections, we would review drug encapsulation and conjugation approach in terms of
formulation design, interaction between drug and polymer backbone for enhanced drug
loading, drug release, and how the existing information can be utilized to design smart
nanoparticles.
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Figure 2-2.

Nanoparticles mediated drug delivery.

Poor extravasation of nanoparticles across endothelium of vital organs and enhanced
permeability and retention of nanoparticles at tumor site result in preferential tumor
distribution of chemotherapeutics. To harness full potential of nanoparticles based drug
delivery, release rate constant of drug (Kr) from nanoparticles should be much smaller
as compared to distribution rate constant (Kd) to prevent premature release of drug from
nanoparticles while in circulation.
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2.3.1 Nanoparticles for drug delivery
Low solubility of anticancer drugs is the major obstacle for systemic therapy.
Nanomedicines have been extensively explored for the delivery of lipophilic drugs.
Hydrophobic core of an amphiphillic polymer improves solubilization of poorly soluble
drugs and has reduced toxicity compared to solubilization of drugs in cosolvent.
Amphiphillic polymers encapsulate the drug based on non-covalent interactions like
hydrophobic interaction, π-π stacking, hydrogen bonding and ionic interactions.
Variety of PEG amphiphilic polyester and polyamide copolymers like poly(ethylene
glycol)-b-poly-(aspartic acid) [PEG-b-PAA] (27), poly(ethylene glycol)-b-poly(lactide- coglycolic acid) [PEG-b-PLGA] (28), poly(ethylene glycol)-b-poly(caprolactone) [PEG-bPCL] (29) and poly(ethylene glycol)-b-poly(D,L-lactide) [PEG-b-PDLLA] (30) with
biodegradable hydrophobic cores have been widely studied for formulation of poorly
soluble drugs as nanoparticles. Key properties of these nanoparticles such as size,
thermodynamic stability, drug loading and drug release kinetics have also been well
reported (31-34). These studies have shown that non-covalent entrapment of drugs into
nanoparticles is restricted by the lack of kinetic stability of polymer nanoparticles upon
dilution, poor drug loading and premature release. To improve the nanoparticle stability
and drug loading, copolymers have been modified to enhance non-covalent interactions
like hydrophobic interaction, π-π stacking, hydrogen bonding and ionic interaction s
between polymer and drugs (34-36). In this section, we would review the different
modification of the nanoparticle core based on the drug characteristics and the critical
role of drug properties in designing the core of micelles.
2.3.1.1

Hydrophobic interaction
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Polymer/drug compatibility has been proposed as the key criteria affecting drug
encapsulation within the core of micelles. Based on polymer/drug compatibility and
thermodynamics, drug solubilization within micelles have been predicted which
correlated well with the experimental findings (37). Polymer/drug compatibility has been
characterized by the Flory–Huggins interaction parameter (χFH) which accounts for the
forces of interaction between the polymer and the drug; and low χFH values suggest
that the polymer is thermodynamically a good solvent for the drug (38, 39). We have
previously modified the core of PEG-PLA to decrease χFH between polymer and
bicalutamide. Introduction of the carbonate monomer within the core enhanced the
interaction between bicalutamide and the core, minimized the χFH resulting in improved
bicalutamide loading and enhanced stability (40, 41). Similarly, encapsulation of
embelin was enhanced inside the core of polymeric micelles by modifying the carbonate
core with dodecanol. Hydrophobic interaction of the long aliphatic chains of embelin
within the core was improved by insertion of long aliphatic chain dodecanol. Interaction
between the aliphatic chains enhanced the thermodynamic stability by reducing the
critical micellar concentration (CMC) values and slow release of embelin from the
micelle core (42). Mahmud et al. also reported chemical tailoring of the core with
cholesteryl moieties to enhance the cholesterol-compatible Cucurbitacin I in the
polymeric micelles (43). Increase in the drug/ polymer compatibility also affects the rate
of drug release as higher drug compatibility with the micelle core results in a
considerable decrease in the drug release rate as evident from the sustained release of
Amphotericin B from fatty acid modified core of PEG-b-poly (amino acid) (43).
Hydrophobic interaction can be critical for effective solubilization of a drug lacking
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hydrophilic groups for other non-covalent interactions and compatibility between drug
and micelle core should be evaluated for effective delivery by nanoparticles.
2.3.1.2

π-π stacking

Interaction between π clouds of aromatic rings of DNA base pairs has been well
studied and this π -π stacking has been utilized for design of nanoparticles. Polymeric
core has also been designed to facilitate the π -π stacking between the core and drug
as most of the poorly soluble drugs contain aromatic rings which can participate in the
π stacking and thereby, improve the stability of polymeric micelles with enhanced drug
loading and sustained release. Kataoka et al have shown that dimers of DOX and DOX
interacted with benzyl residue of poly (ethylene glycol)-poly(beta-benzyl-L-aspartate)
block copolymer through π- π stacking. π- π stacking between the anthracycline
moiety of DOX and benzyl side groups of polymer segment improved drug loading,
exhibited sustained release and stabilized the micelles upon dilution (44). Several other
groups also have attributed improved drug loading and self-assembly of DOX to the
presence of aromatic group in the hydrophobic block of polymers (45, 46). PTX loading
of % 34 has been reported with aromatic modification of N-(2 hydroxypropyl)
methacrlyamide (HPMA) based micelles. Conjugation of benzoyl or naptholyl derivative
to HPMA allowed π- π interaction with PTX which was confirmed by 1H solid-state
NMR spectroscopy. π- π interaction between PTX and the aromatic core improved the
drug retention within the core as evident from slow release (47).
π- π interaction also plays a critical role in enhancing the solubility of drugs by
hydrotrophy. Hydrotropic molecules are believed to undergo aggregation by a stacking
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mechanism of the planar aromatic ring present in their chemical structures. Lee et al
designed amphiphillic polymers grafted with hydrotropic agents to the hydrophobic block
of the copolymer. High local concentration of hydrotropic agents within the core allowed
π- π stacking and solubilization of poorly soluble drugs within the core by hydrotrophy.
Structural activity relationship of 60 hydrotropic agents confirmed the presence of
pyridine and benzene rings within the hydrotropes is essential for solubilization of drugs
and thereby confirmed the role of π- π interaction in polymer hydrotropes (48).
Moreover, the presence of aromatic rings within the drug is also essential for solubility
enhancement by hydrotropes which further confirmed the π- π stacking as the
potential mechanism of the solubilization (49). These studies reflect that core of the
polymer can be modified to amplify theπ- π interaction between the drug and the core
for enhanced dynamic stability of nanoparticles, increased drug loading and sustained
release.
2.3.1.3

Hydrogen bond and ionic interaction

Core of the micelles has been manipulated to improve the drug loading of weakly
acidic and basic drugs. Micelle core containing carboxylic acid has been extensively
reported for encapsulation of anticancer drugs DOX and cisplatin (27, 50-53). Ionic
interaction between amino group of DOX (pka =8.25) and polymer with carboxylic group
resulted in significantly high drug loading and pH dependent DOX release. Strong ionic
interaction between cationic drug and polymer is an enthalipically driven process and
the encapsulated drug exhibited stoichiometry proportion of 1:1 to molar concentration
of carboxyl group of polymer. Loading of polymer bound drug by ionic interaction is
further enhanced by stacking interactions among the drug molecule (54). Similarly,
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Borsali et al. reported high loading capacity and pH dependent drug release for weakly
acidic drugs containing carboxyl functional groups. Core of PEG-poly acrylates was
modified with the amino groups to design micelles with weakly basic core. Micelles with
weakly basic core resulted in high drug loading of % 50 w/w, which reversed upon
esterification of carboxylic groups of these drugs. Role of the acid-base interaction was
further confirmed by poor loading capacities with nonionic polyester block copolymers
(55). These studies indicate that weakly acidic and basic drugs can be effectively
encapsulated at high loading with the modified core of the micelles.
Majority of drugs contain carbonyl groups, hydroxyl groups and amine group which
could act as hydrogen-bonding sites. Polymers have been designed for hydrogen bond
interaction between the micelle core and hydrogen-bonding sites of the drugs.
Hamaguchi et al. reported enhanced drug loading and stable micelles of PTX by
modification of the polyaspartate block by 4-phenol-1-butanol. Hydrogen bond
interaction between 4-phenol-1-butanol and PTX significantly improved the micelles
stability followed by sustained release. This enhanced stability improved the tumor
accumulation by 25 fold as compared to free PTX and significantly reduced the
associated neurotoxicity further improving the therapeutic profile of PTX (56). Core of
the poly-glutamate was grafted with aliphatic, aromatic hydrocarbons and polar side
chains to evaluate the effect of hydrogen bond on micellar formulation of PTX. Although
blank micelles containing polar groups were thermodynamically less stable, they
showed enhanced drug loading, kinetic stability and sustained release of PTX. These
enhanced stabilization is due to the additional stabilization by hydrogen-bonding
interaction between the polar groups grafted micelle core and the encapsulated PTX
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(57). Hydrogen bond interaction has also been utilized to improve the kinetic stability of
micelles. Modification of the core of micelles with the urea which is known to associate
through bifurcated hydrogen bonds has been reported (58). These urea-containing
polymers stabilized micelles by hydrogen bonding Interactions leading to greater kinetic
stability with narrow size distribution and high cargo loading capacity . These studies
underline the significance of hydrogen bond and ionic interactions in formulation of
kinetically stable nanoparticles with high drug loading capacity and sustained release.
2.3.2 Polymer-Drug conjugate
Functional groups of certain drugs and their prodrugs allow covalent conjugation to
the polymers for their formulation into nanoparticles. Molecular weight, conjugation
chemistry, and biodegradability are the key properties which affect the biodistribution
and efficacy of polymer-drug conjugate (59, 60). For efficient plasma circulation and
tumor accumulation, ideally molecular weight of the polymer-drug conjugate should be
higher than 40 kDa as renal threshold for polymer elimination is approximately 30-40
kDa (61). However, application of high molecular weight polymer may be limited by
non-degradable nature of certain polymers and a balanced approach is required
between renal elimination and enhanced tumor accumulation by EPR effect. Stability of
polymer-drug conjugate in the circulation depends upon the covalent chemistry as well
as molecular architecture of polymer-drug conjugate (61). Ester, amide, hydrazone and
enzyme sensitive linkers have been reported for conjugation of numerous drugs. This
different chemistry has been utilized to synthesize polymer-drug conjugate which are
stable in plasma but would release the drug at the tumor site at a desired rate. In
general, ester bonds undergo rapid hydrolysis contributing to poor stability in plasma

19

whereas poor hydrolysis of amide bond restricts the release of drug at the tumor site. To
resolve this, polymer drug linkers have been designed for intracellular or tumor specific
release of the drug. Among the linkers, tetrapeptide sequence Gly–Phe–Leu–Gly
(GFLG) for cleavage by lysosomal proteases (especially cathepsin B) has been widely
studied for intracellular drug release (62, 63). However, intracellular drug release from
these conjugates is limited by poor cellular uptake of these hydrophilic polymer-drug
conjugate which is reflected by higher in vitro IC50 of these conjugates (64, 65). An ideal
polymer-drug conjugate should be biodegradable, non-immunogenic, stable in plasma
and exhibit rapid cell uptake followed by intracellular enzymatic hydrolysis or
extracellular release at desired rate. In the following section, we would review the
different polymers which have been extensively studied for polymer-drug conjugate.
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Figure 2-3.

Chemical structure of polymeric backbone used for formulation
of polymer-drug conjugate.
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2.3.2.1

Polyethylene glycol (PEG)-drug conjugate

PEGylation of drugs and proteins is well-established and has been extensively used
in clinically approved products. Excellent biocompatibility and end group chemistry
allows efficient conjugation of drugs to PEG (Figure 2.3). PEG with COOH, NH2, OH or
SH reactive functional groups has been synthesized to conjugate drugs and proteins.
Covalent conjugation of PTX, methotrexate (MTX), cisplatin, gemicitabine and
camptothecin leading to the formation of ester, amide or disulphide bond has been
reported. Enzon has reported the water soluble PEG-PTX conjugate of 40 kDa with 4%
loading and equivalent in vivo toxicity (66). Renal threshold for clearance of PEG is
approximately 20 kDa and the circulation half-life of PEG dramatically increases from 18
minutes to 16.5 hours as the molecular weight is increased from 6 kDa to 50 kDa (67).
However, the utilization of high molecular weight PEG is limited by its non-degradable
nature. To overcome this potential challenge, PEG with heterobifunctional reactive
groups has been synthesized to attach PEG to nanoparticles (68, 69). Polyester units of
PEG copolymer increase the molecular weight of PEG-drug conjugate and are also
biodegradable in nature. Unlike PEG-drug conjugate, PEG polyester copolymer-drug
conjugate are generally amphiphillic and forms nanoparticles.
There are no reported studies to characterize and quantify kinetics of the cellular
uptake of PEG-drug conjugate. Krtaz et al have reported the synthesis of PEG-MTX
conjugate of molecular weight ranging from 750 to 40000 Da. All the conjugates
exhibited 60-200 fold increase in IC50 values despite the similar inhibitory action on
dihydrofolate reductase enzyme in cell free system (70). This increase in IC50 value can
be attributed to either inefficient cellular uptake or slow hydrolysis of free drug in the
cytosol. Hydrolysis of drug as rate limiting step can be ruled out as even rapid release of
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DOX from PEG-DOX conjugates with GFLG linker exhibited much higher IC50 as
compared to free drug. These studies confirmed that cellular uptake rather than drug
release from PEG-drug conjugate results in higher IC50 values of PEG-drug conjugate
(71). Veronese et al. studied poly(ethylene glycol) PEG-doxorubicin (Dox) conjugates
of linear or branched architecture of different molecular weight and with different
peptidyl linkers (GFLG, GLFG, GLG, GGRR, and RGLG). Rapid hydrolysis of GFLG
linker by lysosomal enzymes in vitro resulted in approximately 57% DOX release at 5 h,
as compared to the other linkers (<16% release at 5 h). Highest molecular weight PEG
had the longest plasma residence time and consequently the greatest tumor targeting
with significantly lower anthracycline levels in heart which highlights the favorable
biodistribution by PEG-drug conjugate (71). PEG-drug conjugate has been pre-clinically
tested for numerous anticancer drugs but challenges like limited capacity for drug
conjugation, poor cellular uptake and non-degradable nature restricted further clinical
development of PEG-drug conjugate.
2.3.2.2

N-(2 Hydroxypropyl) methacrlyamide (HPMA) drug conjugate

Application of copolymers of HPMA as drug conjugate was pioneered by Kopecek
and co-workers (72). Mainly, HPMA copolymer intermediates for conjugation are
synthesized by free radical polymerization using HPMA and methacryloylated (MA)peptidyl-nitrophenylester as comonomers (Figure 2.3). Facile synthesis of HPMA
copolymer allowed incorporation of different functionalities with precise control of
molecular weight and composition. HPMA polymer backbone is non-degradable limiting
the molecular weight of polymer-drug conjugate below 40,000 kDa to ensure eventual
renal elimination. HPMA copolymer-GFLG-DOX-conjugate has been extensively studied
clinically. HPMA-DOX conjugate demonstrated enhanced blood levels of DOX with four
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to five fold increase in the maximum tolerated dose (73). By contrast, HPMA conjugates
of PTX and camptothecin did not show significant improvement from parent molecules.
This was attributed to poor plasma stability of ester conjugation of drugs to polymeric
backbone which highlights the importance of optimization of conjugation chemistry (74,
75). Etrych et al. reported synthesis of HPMA-PTX conjugate through pH sensitive
hydrazone bond (76). HPMA-PTX conjugate through hydrazone bond showed
enhanced plasma stability with drug release at mild acidic conditions (pH= 5). However,
further clinical translation of HPMA-drug conjugate is limited by rapid renal elimination
with 50–75% elimination over 24 h (73). To use high molecular weight HPMA-drug
conjugate, Yang et al reported synthesis of high molecular weight HPMA–drug
conjugate which contained enzymatically degradable bonds in the polymer backbone.
This high molecular weight multiblock HPMA copolymer with enzymatically degradable
linker between HPMA blocks with molecular weight distributions below the renal
threshold were reported for delivery of gemcitabine (77). Increase in molecular weight of
the second-generation enzyme degradable HPMA-drug conjugates resulted in distinct
advantages as improved pharmacokinetics (three- to five-times half-life compared with
the first generation), and dramatically enhanced tumor inhibition (78). Future clinical
translation of HPMA-drug conjugate would depend upon synthesis of second-generation
long circulating HPMA-drug conjugates and selective release of drug at the tumor site.
2.3.2.3

Polyglutamate (PG)-drug conjugate

Polyglutamate (PG) is composed of degradable amide bond unlike non-degradable
carbon-carbon backbone of PEG and HPMA. PG is generated from hydrolytic removal
of benzyl group of poly (γ- benzyl -L- glutamate) and carboxyl group of pendant free PG
is utilized for drug conjugation (Figure 2.3). PG-drug conjugates are water soluble and
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acquire α helix or random coil structure depending upon the pH of the surrounding
media. PG is stable in plasma and long circulation time allows accumulation at tumors.
PG like other macromolecules is extensively secreted by kidney and follows the renal
threshold cut off for water soluble polymers (79). High molecular weight PG has been
shown to activate the fibrinolytic system and week immunogenic response depending
when the PG-drug conjugates are administered (80). Li et al. has done extensive work
on PG-drug conjugates and extensively characterized PG-drug conjugate of numerous
drugs (81).
PG-anthracycline conjugates have been reported using ester, amide, peptide and
hydrazone linkers (82-84). All of the PG conjugates have higher in vitro cytotoxicity
compared to the free drug. This is attributed to the slow release of the free drug from
PG-DOX conjugate. Preclinical data have shown that the conjugate with oligopeptide
spacer were active, whereas conjugates without degradable spacers were completely
inactive. Increase in the rate of DOX release with increase in the length of spacer
improved in vitro and in vivo anticancer effect of PG-DOX conjugate (85). Water soluble
PG-PTX conjugate was also synthesized through ester linkage of 2’ hydroxyl group of
PTX.

PG-PTX conjugate exhibited remarkable high loading of 37% and stability in

plasma due to molecular architecture. Cellular uptake of radiolabeled PTX and PG
backbone suggested that PTX is hydrolyzed extracellularly which was taken up by cells
(64). PG-PTX exhibited excellent efficacy in different cancer models as PG-PTX
exhibited enhanced circulation in comparison to free PTX and released the drug in the
vicinity of tumor (86). PG-PTX has shown excellent safety with equipotent efficacy in
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variety of cancer in Phase III trials and highlights the future potential of PG-drug
conjugate based nanoparticles.
2.4 Nanoparticles for photodynamic therapy and detection
Photodynamic therapy (PDT) is an exciting detection and treatment modality for
melanoma. PDT is based on the excitation of photosensitizer at a specific wavelength of
light after preferential tumor accumulation of photosensitizer. Nanoparticles for PDT can
be designed for metastasis detection, destruction of bulk tumor and cancer stem cells
(CSCs), for photoimmunothrepay and for improving drug delivery at both tumor and
cellular level. Galanzha et al reported a novel diagnostic and therapeutic platform with
gold carbon nanotubes. Noninvasive in vivo detection and treatment of metastatic
melanoma at single cell level was achieved after administration of gold carbon
nanotubes by using a combination of PA imaging and photothermal (PT) therapy (87).
Nanoparticles labeled with CSCs markers allowed detection and ablation of CSCs by
multifunctional PAFC/PTFC nanoparticle based platform. CD44 labelled gold carbon
nanotubes enabled ultrasensitive detection of CSCs in vivo (88). PT with antibody
labeled nanoparticles selectively targeted and eradicated CSCs (89, 90). These studies
highlight the immense potential of nanotechnology based PDT in detection and
treatment of circulating tumor cells and CSCs.
Destruction of primary tumor lesion with modulation of immunity against the tumor
antigen is potential therapeutic option against metastatic melanoma (91, 92).
Photoimmunotherapy, combination of PDT and immunomodulation using adjuvant has
demonstrated significant benefits in late stage metastatic melanoma (93, 94). PDT with
indocyanine green (ICG) followed by local application of immunostimulant imiquimod
resulted in beneficial systemic response against metastatic melanoma (93, 94). To
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further improve tumor selective delivery of both immunostimulant and photodynamic
agents, nanoparticles have been formulated (95). Bear et al. demonstrated PDT with
gold nanoparticles in combination with adoptive T cell transfer prevented primary tumor
recurrence post-ablation, inhibited tumor growth at distant sites, and abrogated the
outgrowth of lung metastases (96). Also, nanoparticles co-delivering photodynamic
agent and immunostimulant exhibited excellent anticancer effect against primary treated
and distant untreated tumors. Chitosan-coating around hollow CuS nanoparticles
allowed incorporation of the immunoadjuvants containing the cytosine-guanine (CpG)
motifs. NIR irradiation triggered disintegration of CuS nanoparticles, allowing the
complexation of chitosan and CpG motifs. Nanocomplexation of CpG motifs enhanced
their tumor retention and uptake by plasmacytoid dendritic cells (95).
High tumor interstitial pressure and inefficient EPR effect can restrict the drug
delivery by nanoparticles. PDT has been shown to improve the nanoparticle mediated
drug delivery by reducing interstitial pressure and enhancing tumor vessel permeability.
PDT resulted in ∼2.5-fold higher tumor uptake at 3 h after administration of liposomal
DOX by enlarging the endothelial gap of tumor vessels (97). PDT selectively enhances
tumor accumulation of

nanoparticles mediated

chemotherapy as intratumoral

accumulation of free DOX after PDT did not change. Tumor vessel targeted delivery of
photosensitizer was achieved by arginine–glycine–aspartic acid (RGD)-modified ferritin.
Ferritin encapsulating photosensitizer hexadecafluoro zinc phthalocyanine located to
the endothelium of neoplastic vessels via RGD–integrin interactions. Photoradiation of
tumor vessel located photosensitizer increased the vascular permeability of albumin,
quantum dots, and iron oxide nanoparticles by as much as 20 fold with no adverse
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effects to normal tissues. Enhanced tumor permeability by PDT improved the
therapeutic efficacy of liposomal DOX by 75.3% highlighting the potential of PDT in
improving the delivery of chemotherapeutics by nanoparticles (98).
Photochemical

internilzation

(PCI)

was

established

at

Norwegian

Radium

Hospital for cytosolic delivery of therapeutic agents entrapped in endocytic vesicles
(99). PCI has been extensively studied for cytosolic delivery of toxins, oligonucleotides,
weakly basic drugs like DOX and cisplatin and can be therapeutically exploited for
overcoming resistance by efflux transporters as well as intracellular sequesterization of
drugs (100-102). Light mediated activation of endocytosed amphiphillic photosensitizer
generates reactive oxygen species which damages membrane of endocytic vesicles
and thereby leading to cytosolic delivery of therapeutic agent. Nanoparticles
encapsulating phthalocyanine upon radiation exhibited PCI properties and facilitated
DOX release from the endo-lysosomes to nuclei.

This increase in intracellular

concentration of DOX resulted in significant reduction in tumor volume (103).
Nanoparticles of weakly basic drugs, oligonucleotides and toxin are excellent
candidates for combination therapy with PCI as they accumulate in endolysosomes
compartment after cellular uptake (104, 105).

PCI mediated cytosolic delivery of

immunotoxins saporin and gelonin have been studied melanoma xenograft model (101,
106).

PCI improved the anticancer response effect of immunotoxins and complete

regression was observed in 33% of tumor-bearing mice (101).

All these studies

highlight the multifold potential of PDT and can be combined with chemo and
immunotherapy for metastasis detection, destruction of bulk tumor cells and CSCs and
for improving drug delivery in melanoma.
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2.5 Active targeting of nanoparticles to melanoma
Passive targeting by EPR effect of nanoparticles improves tumor accumulation but
do not enhance the cellular uptake and depends upon the convective transport of
nanoparticles against high interstitial pressure (107). To further improve the therapeutic
efficacy of nanoparticles, interaction between receptor and ligands has been exploited
for active targeting of nanoparticles (108). Peptides, antibodies, small molecules and
aptamers have been extensively studied to accomplish active targeting of nanoparticles
(109).

Nanoparticles

for

active

targeting

against

tumor

vasculature,

stromal

microenvironments and cell surface receptors have been investigated in preclinical
models of melanoma.
Endothelial cells of tumor neovasculature overexpress αvβ3 integrin receptor in
comparison to low or negligible expression by normal vasculature (110). αvβ3 integrin
receptor not only promotes angiogenesis but also supports melanoma growth,
adhesive, invasive and migratory properties of the melanoma tumor cells (111).
Tripeptide motif RGD, cell adhesion peptide sequence in ECM proteins and its
derivatives been extensively studied for design of αvβ3 targeted nanoparticles (112).
Benzera et al. reported significant increase in tumor-to-blood residence time ratios, and
tumor-selective accumulation with cyclic RGD peptide ligands modified silica
nanoparticles in melanoma xenograft mouse model (113). Surface modification of DOX
loaded nanoparticles with DI17E6, a humanized monoclonal antibody against αvintegrins enhanced the integrin receptor specific cellular uptake in melanoma M21 cell
line. Targeted nanoparticle reduced the integrin mediated attachment of cells to ECM
proteins with enhanced cell cytotoxicity. Enhanced alpha integrin mediated uptake of
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DOX loaded nanoparticles significantly reduced the IC50 from 55 to 8 nm in integrin
positive melanoma cell line (114).
Progression of melanoma is associated with stromal changes contributing to
uncontrolled growth and invasive behavior of melanocytes. These characteristic stromal
changes have been exploited to target nanoparticles to tumor stroma. Secreted protein
acidic and rich in cysteine (SPARC) a nonstructural matricellular protein has been well
studied in the tumorigenicity and progression of melanoma (115-117).

Peptide

sequence with high affinity and specificity for SPARC protein has been identified by
phage display.

SPARC targeting peptide modified nanoparticles exhibited high affinity

with negligible binding in negative cell lines. Targeting of nanoparticles to SPARC did
not alter their blood clearance but there was a 45 fold increase in tumor accumulation of
SPARC targeted nanoparticles as compared to the control group. Moreover, SPARC
labeled proteins allowed detection of metastatic growth in addition to primary tumors
(118). Albumin also exhibits SPARC binding properties and enhances the tumor
accumulation of albumin nanoparticles (119-121). Albumin bound PTX nanoparticles
(nabPTX) exhibited enhanced response in SPARC overexpressing xenograft in
comparison to wild type PC3 tumor xenograft (120). However, these results are largely
correlative with small sample size. Also, there are studies which demonstrated efficacy
of nabPTX independent of SPARC expression (122-124). Tumor stroma also contains a
mesh network of fibrin and fibronectin. Pentapetide CREKA has been reported to bind
to this mesh like network and further enhances the formation of clot like mesh at the
target

site.

CREKA labeled

nanoparticles and

liposomes showed

enhanced

accumulation in tumor vessels with induction of additional localized clotting and thereby
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producing new binding sites for more particles. This clotting-based amplification greatly
enhanced tumor imaging with envision of the design of drug-carrying self-targeting
nanoparticles (125).
Cancer cells overexpress receptors for cellular uptake of essential nutrients to meet
their high proliferation rate. Transferrin receptor, a type II transmembrane glycoprotein
is overexpressed by cancer cells to meet growing demands of iron (126). Targeting
overexpression of transferrin receptor with its ligand, transferrin has been extensively
studied for targeted delivery of nanoparticles (126). Davis et al reported the first in
human clinical trial with transferrin targeted nanoparticles (127). Targeted nanoparticles
exhibited dose dependent localization within transferrin positive melanoma tissue with
little localization in the adjacent epidermis. Intracellular delivery of nanoparticles was
observed only in the transferrin targeted nanoparticles which highlights the need of
targeted nanoparticles for intracellular delivery (128, 129). Altered glycosylation patterns
are a hallmark of the malignant growth. Proliferation of cancer cells is associated with
enhanced sialylation of N linked glycans and this altered glycosylation enabled the
design of sialic acid targeted nanoparticles (130, 131). Phenylboronic acid (PBA)
reversibly binds with 1,2- or 1.3-diols, which are major constituent of glycan. PBA-sugar
complexes are unstable at plasma pH, however PBA forms extremely stable complex
with sialic acid at physiological pH (132). This tumor specific sialic acid recognition at
physiological pH with controlled pKa of PBA, have been studied as a molecular basis for
the design of targeted nanoparticles. Deshayes et al. reported the design of PBA
modified nanoparticles for enhanced delivery to melanoma (133).

PBA targeted

nanoparticles exhibited higher tumor accumulation level indicating interaction of PBA
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targeted nanoparticles with the sialic acid moieties on the surface of cancer cells
improved the retention of nanoparticles at the tumor site. PBA targeted nanoparticles
demonstrated improved efficacy as compared to non-targeted nanoparticles correlating
with their enhanced accumulation in tumors.
Progression of melanoma is associated with expression of high levels of the
melanocortin type-1 receptor (MC1R) making it one of the melanoma specific targets for
highly sensitive detection and therapy of metastatic melanoma (134).

α-MSH, a

tridecapeptide and its derivatives have been investigated for melanoma specific
targeting (135). Conjugation of MSH derivative as targeting moiety significantly reduced
the tumor burden upon PDT with gold nanoparticles. Receptor mediated uptake of
targeted nanoparticles resulting into the enhanced tumor nanoparticle levels caused
significantly greater necrotic response than non-targeted nanoparticles. Targeting
improved the nanoparticle distribution within the tumor matrix as suggested by their
presence at >200 μm away from the nearest blood vessels whereas non-targeted were
scattered only adjacent to tumor vasculature. Enhanced retention and uptake was
confirmed by co-localization of targeted nanoparticles and MC1R (136). Similarly,
targeting MC1R raised the sensitivity and specificity of PA imaging with gold nanocages
by 300 %. Interaction between MC1R and targeting ligand enhanced nanoparticle per
tumor mass by 360 % highlighting that targeted systems can detect early stage
melanomas metastatic lymph nodes, and can be potentially used to treat the
melanomas (137). Besides MC1R, chondroitin Sulphate Proteoglycan 4 (CSPG4) is a
highly specific marker of the nevomelanocyte lineage and has been utilized for targeting
melanoma. Ep1 monoclonal antibody to the human melanoma-specific antigen CSPG4
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targeted nanoparticles showed a 25-fold preference for melanoma as compared to nontarget cells. Selectivity for melanoma was also confirmed in xenograft models where
targeted nanoparticles significantly inhibited growth of melanoma xenograft with little
effect in breast carcinoma xenograft (138). This all studies highlight the potential of
active targeting to improve the outcome of nanoparticle based therapy. However, tumor
heterogeneity and translation of preclinical xenograft data to human tumor are the major
roadblocks.
2.6 Conclusion
Numerous anticancer drugs have been discovered through advancement in the
molecular biology and drug discovery. All these anticancer drugs exhibit excellent
efficacy in petri dishes but fail during translation to clinic. BRAF and MEK inhibitors
show remarkable response in initial therapy but resistance develops invariably.
Moreover, non-specific distribution of BRAF inhibitors leads to malignant and benign
growth including squamous cell carcinomas and other severe dermatological side
effects (139, 140). Combination therapy to overcome the potential resistance
mechanism is the way forward for preventing the relapse. However, unfavorable
physicochemical properties and pharmacokinetic profiles limit the clinical application of
conventional

chemotherapeutics as

combination

therapy.

Nanoparticles based

formulation approach to minimize peripheral exposure and to maximize tumor
accumulation can be exploited to overcome these potential roadblocks.
Significant progress has been made since the idea of polymer based delivery was
first conceived (141). Active targeting strategies using stimuli sensitive and receptor
targeted nanoparticles have been devised to further augment the application of
nanoparticles based delivery of chemotherapeutics. Despite of all these efforts, there
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are limited numbers of approved nanoparticles based products which is due to
challenges associated with the formulation of kinetically stable nanoparticles with high
drug loading, and controlled release. It would require a concerted effort between drug
discovery and formulation scientist to maximize the interaction between polymer and
drugs for optimum design of nanoparticles based drug delivery.
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CHAPTER 3 MICELLAR FORMULATION OF INDOCYANINE GREEN FOR

PHOTODYNAMIC THERAPY OF MELANOMA
3.1 Introduction
Lack of selectivity of chemotherapeutics towards tumor tissue and their dose limiting
toxicity led to the development of alternative therapeutic approaches (142).
Phototherapy (PT), a combination of photodynamic therapy (PDT) and photothermal
therapy (PTT) represents such an approach with improved selectivity and lesser side
effects as compared to conventional radiotherapy and chemotherapy. PT involves the
administration of non-toxic photosensitizer (PS) followed by its excitation with the light of
specific wavelength which leads to the generation of local heat and reactive oxygen
species (ROS) particularly singlet oxygen. Tumor selective radiation of PS followed by
localized generation of ROS and heat results in selective and efficient destruction of
cancer with no or minimal toxicity to normal tissue (143).
Currently, all the food and drug administration (FDA) approved PS absorb in the
visible spectral regions restricting light penetration into the skin to only a few millimeters
which limits the clinical application of PT for treating topical lesions only (144). The
near-infrared (NIR) PS has relatively low tissue absorption, low scattering and minimal
auto fluorescence allowing deep tissue penetration for PT. Indocyanine green (ICG), a
water soluble anionic tricarbocyanine dye is the only FDA approved NIR agent which
has been widely utilized clinically for medical imaging and hepatic function diagnosis
(145). ICG strongly absorbs light around 800 nm with minimal scattering and
fluorescence interference by biomolecules at this wavelength.
In spite of the excellent safety profile and absorption in the NIR range, short half-life
(2-4 minutes) and limited extravascular distribution restricts PT application of ICG. ICG
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binds to HDL3 lipoprotein, albumin and undergoes extensive hepatobiliary secretion
restricting its peripheral distribution and sufficient tumor accumulation for PT (146). To
prolong its systemic circulation and improve tumor distribution, various formulations of
ICG prepared with polyallylamine, calcium phosphate, polymer, hyaluronic acid,
liposomes, silica nanoparticles and carbon nanotubes have been reported (147-153).
However, poor loading, rapid release and large particle size of these reported ICG
formulations nullify the advantages associated with their delivery (149, 151). Noncovalent interactions between ICG and nanoparticle matrix is the primary mechanism
for physical encapsulation of ICG in these reported nanoparticles system. Non-covalent
interactions are weak in nature which results in the moderate ICG loading and rapid
release upon in vivo dilution.
To address these limitations, we have covalently conjugated amino derivative of ICG
to the pendant carboxylic group of a biocompatible and biodegradable amphiphillic
copolymer. ICG conjugated amphiphillic polymer self-assembled into micelles of 50 nm
with improved ICG loading and little premature ICG release. ICG conjugated micelles
were evaluated for their cellular uptake and photodynamic toxicity.

In vivo

biodistribution and tumor accumulation of ICG conjugated micelles was evaluated using
non-invasive NIR fluorescence imaging. Finally, the efficacy of PT of ICG conjugated
micelles was studied after light irradiation in A375 human melanoma tumor in athymic
nude mice.
3.2 Materials and Methods
3.2.1 Materials
2, 2-Bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG,
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Mn

=

5000),

8-diazabicycloundec-7-ene

(DBU),

1-(3-dimethylaminopropyl)-

3-

ethylcarbodiimide HCl, 1-hydroxybenzotriazole (HOBT) benzyl bromide, acridine
orange, dodecanol and diisopropylethylamine (DIPEA) were purchased from Sigma
Aldrich (St. Louis, MO) and were used as received.

Singlet oxygen sensor green

(SOSG) reagent, DMEM medium, Lysotracker red, Calcein AM and propidium iodide
were purchased from Invitrogen (Carlsbad, CA). All other reagents were obtained from
Sigma–Aldrich (St. Louis, MO) unless otherwise stated and were used as received.
3.2.2 Synthesis of 2-Methyl-2-Benzyloxycarbonyl-Propylene Carbonate (MBC)
Monomer

2-methyl-

2-benzyloxycarbonyl-propylene

carbonate

(MBC)

was

synthesized as described previously. Briefly, a mixture of 0.168 mol 2, 2bis(hydroxymethyl)propionic acid and 0.169 mol potassium hydroxide was dissolved in
125 mL of dimethylformamide (DMF) by heating to 100 °C for 1 h with stirring. 0.202
mol benzyl bromide was added dropwise to the warm solution and stirred at 100 °C for
16 h. At the end of reaction, the solvent was removed under reduced pressure and
residue was dissolved in 150 mL of ethyl acetate, washed with water, and dried over
MgSO4. Ethyl acetate was removed to yield a crude product, which was recrystallized
from toluene to give pure benzyl 2, 2-bis(methylol)propionate. To synthesize 2-methyl-2benzyloxycarbonylpropylene carbonate (MBC), 0.05 mol benzyl 2,2-bis(methylol)propionate was dissolved in 150 mL of CH2Cl2 containing 25 mL of pyridine, and the
solution was chilled to - 78 °C. A solution of CH2Cl2 containing 25 mmol triphosgene
was dripped into the solution over 1 h. The reaction mixture was stirred for an additional
2h at the room temperature before quenching with 75 mL of saturated aqueous NH 4Cl.
Subsequently, the organic layer was sequentially washed with aqueous HCl (1 M, 300
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mL) and saturated aqueous NaHCO3 (300 mL), dried with Na2SO4, and evaporated to
give 2-methyl-2-benzyloxycarbonylpropylene carbonate (MBC) as a crude product,
which was further recrystallized from ethyl acetate to give white crystals.
3.2.3 Synthesis of mPEG-PCC-g- NH2 ICG -g-DC
mPEG-MBC was synthesized by ring-opening polymerization of MBC and mPEG in
the presence of 1,8-diazabicycloundec-7-ene (DBU) as a catalyst at room temperature
for 3 has described previously (154). The crude polymer so obtained was dissolved in
chloroform and purified by precipitation in isopropanol followed by drying under vacuum
for 48 h. Protective benzyl group of mPEG-MBC was removed by hydrogenation to
obtain free carboxyl group for subsequent conjugation. For this, mPEG-MBC (1 g) was
dissolved in a mixture of tetrahydrofuran and methanol (1:1; 12 mL) containing
palladium on carbon (Pd/C) (200 mg) and charged with hydrogen at a pressure of 55
psi. Reaction was carried out for 18 h after which Pd/C was removed by filtration and
solvent was evaporated under reduced pressure to get poly(ethylene glycol)-blockpoly(2- methyl-2-carboxyl-propylene carbonate) (PEG-PCC).
ICG-NH2 and DC were conjugated to the carboxyl groups of PEG-PCC using
carbodiimide coupling. For this, PEG-PCC (300 mg) was dissolved in 5 mL of DMF
followed by addition of 223 mg of 1-hydroxybenzotriazole (HOBT), 317 mg of 1-(3dimethylaminopropyl)-3-ethylcarbodiimide HCl (EDC), 340 μL of DIPEA and ICG-NH2
and dodecanol (DC) in DMF were added sequentially to the reaction mixture. The
reaction was allowed to proceed for 48 h under nitrogen atmosphere at room
temperature. After completion of the reaction, crude product was purified by
precipitation in large excess of cold isopropyl alcohol. The precipitate obtained was then
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dissolved in DMF, dialyzed against DMF and reprecipitated twice in cold isopropyl
alcohol to obtain mPEG-PCC-g-ICG-g-DC.
3.2.4 Characterization of Polymer and Polymer Drug Conjugate
1

H NMR spectra were recorded on a Bruker AVANCE III instrument (400 MHz, T =

25 °C) using DMSO-d6 as solvent in chemical shift range of 0−13. For GPC, narrow
PEG standards (3600–71000 g/mol) from Polymer laboratories (Santa Clara, CA) were
used for generating standard curve and the data was processed using LC Solution
ver.1.21 GPC option software.
3.2.5 Formulation Development
ICG conjugated micelles were prepared by nanoprecipitation. Briefly, 30 mg of

mPEG-b-PCC-g-NH2ICG-g-DC copolymer was dissolved in acetone (0.5 mL) and added
to 4 mL of PBS (pH 7.4). Acetone was then evaporated under reduced pressure
followed by centrifugation at 5000 g for 5 min. ICG concentration was determined by
comparing absorbance at 790 nm to a standard curve of aqueous ICG-NH2 solution. ICG
loading was determined as expressed as the weight ratio between ICG content from
standard curve and total weight of polymer ICG conjugate. All loading measurements
were performed in triplicate.
3.2.6 Transmission Electron Microscopy
ICG conjugated micelles were visualized using a JEM-100S (Japan) transmission
electron microscope (TEM). Micellar suspension was loaded onto copper grid negatively
stained with NanoVan®. The grid was visualized at 60 kV with magnifications ranging
from 50, 000X to 100,000X.
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3.2.7 Spectroscopic Measurements
Absorption spectra of both ICG solution and ICG conjugated micelles at 5μg/ml were
recorded between 600-900 nm using a slit width of 5nm. Fluorescent spectra of ICG
solution, ICG conjugated micelles and DMSO solution of polymer ICG conjugate was
recorded at the wavelength of 640 and 760 nm using a slit width of 5nm using
fluorescent spectrometer (Spectramax). 10 % Sodium dodecyl sulphate (SDS) was
added to ICG conjugated micelle to disrupt the micelle core and to reverse the
quenching of ICG signal. Disruption of micelle core and dequenching by SDS solution
was studied both qualitatively and quantitatively using Licor Pearl Imaging System and
fluorescent spectrometer (Bruckers) respectively.
3.2.8 Measurement of Singlet Oxygen
ICG conjugated micelles of different concentration (1.0 mL) were irradiated for 3 min
at 1.5 W at 808 nm to measure generation of singlet oxygen. Singlet oxygen sensor
green (SOSG) equivalent to 32.0 μg/mL was added prior to irradiation to monitor the
generation of singlet oxygen. Generation of singlet oxygen was determined by
measuring the fluorescence intensity of SOSG at 525 nm using an excitation
wavelength of 504 nm. The solution of SOSG without ICG was used as the control.
Sodium azide was added during irradiation to quench the generated singlet oxygen and
to observe subsequent reduction in SOSG fluorescence intensity.
To determine intracellular generation of singlet oxygen, A375 cells were seeded on a
24 well plate (5 x 104 cells/well) overnight and incubated with ICG conjugated micelles
at concentrations of 50 μg for 24 h. After 24 h, cells were washed thrice with PBS and
0.02 ml of dihydroethidium (DHE) (50 μM, PBS) was added to the cells for 30 min at 37
ºC as an indicator of reactive oxygen species. Cells were irradiated with a power density
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of 2W at 800 nm for 5 min. Cells were washed with PBS twice and imaged using Zeiss
microscope at an excitation wavelength of 550
3.2.9 In Vitro Photodynamic Toxicity
A375 cells plated at a density of 35000 cells/well in 24 well plate were incubated with
free ICG (2−15 μg) and ICG conjugated micelles at concentration (15-50 μg) for 24 h.
Cells were irradiated with a power density of 2W at 800 for 2 min. Contribution of PDT
and PTT effect towards cell killing was studied by using sodium azide and irradiation at
4 °C to block PDT and PTT effect, respectively. Sodium azide was added to cell culture
medium at 100 mM to quench singlet oxygen and thereby block PDT effect. Cells were
irradiated at 4 °C to maintain constant temperature and nullify the PTT effect. Laser
only, ICG solution and ICG conjugated micelles without radiation exposure were used
as a positive control. After 24h of irradiation, MTT assay was performed to calculate the
cell viability. The absorbance was measured at 560 nm using a microplate reader
(Epoch, BioTek Instruments Inc., Winooski, VT).
Cell cytotoxicity was also determined after 24 h of cellular uptake of ICG conjugated
micelles and ICG solution. Cells were incubated with ICG solution and ICG conjugated
micelles for 24 h followed by three PBS washings. Cells were exposed to NIR radiation
with a power density of 2W at 800 for 2 min followed by MTT assay after 24 h. Viability
staining was also performed on A375 cells using Calcein AM/ propidium iodide. A375
cells were incubated with free ICG solution at 8 μg and ICG conjugated micelles at 30
μg in 24-well plates for 24 h. After 24 h incubation following NIR irradiation, medium was
replaced with 1 mL PBS solution containing 4 μL of calcein AM stock solution (1 mg/mL
in DMSO) and 2 μM propidium iodide solutions for 30 min. Subsequently, each well
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was washed once with PBS and live/dead cells were imaged using Zeiss fluorescent
microscope.
3.2.10 Cell Uptake Studies
A375 cells were seeded in 4 well chambers slides (2 × 10 4 cells/well) overnight and
ICG conjugated micelles were added for 24 h at 37 °C to monitor the uptake of ICG
conjugated micelles. Cells were incubated with the media containing LysoTracker Red
DND-99 (4 μL of 1 mM DMSO solution in 40 mL of media) for 30 min in the dark prior to
washing. After washing thrice with PBS, cells were fixed with 4% paraformaldehyde in
PBS at room temperature for 15 min and then counterstained with DAPI. Cellular uptake
and co-localization of ICG conjugated micelles in lysosomes was imaged using a
confocal microscope.
For quantification of cellular uptake, A375 cells were seeded in 6-well plates (3 × 105
cells/well) and cultured with ICG conjugated micelles (containing 20 μg ICG) and free
ICG (20 μg) in DMEM medium at 37 °C for 4h, 8h and 24 h. At the end of incubation
periods, the cells were washed with PBS thrice and lysed using a lysis buffer. Cellular
uptake of ICG was quantitatively measuring fluorescence intensity of 1:1 dilution of cell
lysate with DMSO at 820 nm upon excitation at 780 nm and calculated by comparing
with standard curve of ICG.
3.2.11 In vivo Imaging
All animal experiments were performed in accordance with the NIH animal use
guidelines and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Nebraska Medical Center (UNMC, Omaha, NE). Athymic
nude mice (6−8 weeks old, weight around 20 g) were used as a tumor model for ex vivo
imaging. Mice were subcutaneously injected with 4 million A375 melanoma cells
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suspended in 200 μL 1:1 serum-free media and Matrigel (BD Biosciences, CA). Mice
were randomly divided into free ICG and ICG conjugated micelles group upon reaching
a tumor volume of 500-1000 mm3. Formulations were administered to mice via the tail
vein at a dose of 2 mg/kg and whole body imaging was performed using LI-COR
Biosciences’s pearl small animal imaging system at 1, 3, and 24 h after dosing. The
average fluorescence intensity corresponding to tumors was calculated and compared
between ICG conjugated micelles and ICG solution groups. To determine the organ
distribution, mice were sacrificed after 24 h of injection, and organs including heart,
liver, spleen, lung, kidney, and tumor were imaged using LI-COR Biosciences’s pearl
small animal imaging system with 800 nm filter. The average NIRF intensity for each
organ was calculated for ICG conjugated micelle and ICG solution groups.
3.2.12 In vivo efficacy study
For efficacy studies, athymic nude mice (8−9 weeks old, weight around 24 g) were
used. Mice were subcutaneously injected with 4 million A375 melanoma cells
suspended in 200 μL 1:1 serum-free media and Matrigel (BD Biosciences, CA).
Animals were randomly divided into three groups when tumor volume was 200 mm3.
Group 1 was kept as the control and received normal saline, group 2 and 3 received
ICG solution (10 mg/kg) followed by irradiation at 1 and 6 h respectively and group
4received ICG micelles equivalent to ICG (10 mg/kg). Tumors were irradiated with laser
at power density of 2 W for 5 min after 6 hours except for group 2. Tumor sizes were
measured after every two days using digital vernier calipers in two perpendicular axis
and reported as tumor volume (V = 1/2[a × b2], a = longest axis, b = shortest axis).
Body weights were measured every 2 days. Tumor tissues were excised and weighed
at the end of study.
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3.2.13 Statistical Analysis
The significance of the results was assessed by Student's t-test. The p-values lower
than 0.05 were considered as statistically significant.
3.3 Results
3.3.1 Synthesis and characterization of NH2 ICG
ICG does not have functional group for its conjugation to the polymeric backbone
and hence amino derivative of ICG was synthesized by Dr. Natarajan’s group as
reported earlier [1]. Synthesis and purity of ICG was confirmed by the LC-MS where a
single peak of 675 Da of amino ICG was observed (Figure 3.1).
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A

B

Figure 3-1.

Synthesis and characterization of amino ICG

(A) Schematic presentation of synthesis of ICG. (B) ICG liquid chromatography trace
for purity was generated on an Agilent 1200 series system with UV detector (256 nm)
using 5-95% acetonitrile as eluent at a flow rate of 1 ml/min and 675 m/z was obtained
using Agilent 1260 LC-MS-ELSD system (bottom).
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3.3.2 Synthesis and characterization of mPEG-b-PCC-g-indocyanine green -gdodecanol (mPEG-PCC-g- NH2 ICG -g-DC)
Synthesis of mPEG-b-PBC polymer was confirmed by 1H NMR and GPC (Figure
3.3). The polymerization and structure confirmation of mPEG-b-PBC polymer was
determined by the peaks at δ 1.2 (CH3 in bicarbonate (BC) unit), δ 3.6 (CH2 in PEG), δ
4.3(CH2 in BC main chain), δ 5.2 (CH2 in BC side group), and δ 7.3 (phenyl ring). Using
the peak integral areas of PEG CH2 groups at δ 3.6 and those of the five phenyl ring
protons in BC at (δ = 7.30 ppm) the number average molecular weight (Mn) of PEG-bPBC was 14500 Da (Figure 3.3A). The polymer molecular weight was 11210 Da with a
polydispersity of 1.14 as determined from GPC standard curve of narrow PEG
standards (Figure 3.4A). The Pd/C catalyzed hydrogenation of benzyl group was
confirmed by disappearance of peaks at δ 5.2 (CH2 in BC side group) and δ 7.3 (phenyl
ring). In addition, a peak at δ 13 was observed indicating the presence of carboxyl
group after removal of protective benzyl group (Figure 3.3B). ICG-NH2 and DC were
coupled to PEG-PCC using EDC/ HOBT coupling chemistry and conjugate was purified.
3.3.3 Formulation development
ICG conjugated polymer was formulated as micelles by nanoprecipitation method.
Particle size of the micelles was determined by transmission electron microscope (TEM)
imaging of vanadium based negative stained micelles which was approximately in the
range of 30-50 nm (Figure 3.4B). TEM images showed spherical micelle with narrow
size distribution. Drug loading of ICG conjugated micelles was 10.2 % by absorption
spectroscopy at 790 nm. Spectroscopic characterization of ICG solution and ICG
conjugated micelles was performed to study the effect of conjugation and micelles
formulation of ICG. Absorption spectrum of ICG conjugated micelles indicated red shift
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of 10 nm upon conjugation and formulation of micelles (Figure 3.5A). Increasing
concentration of ICG is associated with self-quenching which resulted in decrease of
NIR fluorescence intensity. Compared to ICG solution, close packing of ICG molecules
within the core of micelles resulted in self-quenching and significantly decrease in the
fluorescence intensity of ICG micelles (Figure 3.5B & C). Increase in the fluorescence
intensity of polymer-ICG conjugate in the organic solvent confirmed that quenching
within the core of micelles resulted in decrease of fluorescence intensity of ICG
conjugated micelles (Figure 3.5D). Micelles upon interaction with serum and cellular
proteins undergo disassembly and lose their integrity. Surfactants like SDS have been
shown to interact with the core of micelles and disrupt the integrity of micelles. Addition
of 10 % SDS to ICG micelles disrupted the core of micelles with two fold increase in the
fluorescence intensity of ICG conjugated micelles (Figure 3.5 E & F). Disruption of
micelles and dequenching effect of SDS was also confirmed by Licor Pearl imaging
system.
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Figure 3-2.
Schematic representation of synthesis and characterization of
ICG polymer conjugate
(I) Ring opening polymerization of monomer 2-Methyl-2-Benzyloxycarbonyl-Propylene
Carbonate using DBU as catalyst (II) Catalytic hydrogenation of PEG- PBC (III)
Carbodiimide coupling of amino ICG to pedant carboxyl groups of PEG-PCC
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B

Figure 3-3.

1

H NMR of polymers (A) PEG-PBC and (B) PEG-PCC in DMSO-d6.

49

A

B

Figure 3-4.
micelles.

Characterization of synthesized polymer and ICG conjugated

(A) Characterization of weight average molecular weight, number average molecular

weight and polydispersity index using GPC and 1H NMR. (B) TEM image of ICG
conjugated micelles which were stained with vanadium based negative staining. Size of
ICG conjugated micelles was approximately 30-50 nm as determined by TEM image.
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3.3.4 Generation of singlet oxygen
Generation of singlet oxygen in solution was determined by measuring the
fluorescence of SOSG upon irradiation of ICG conjugated micelles. Intracellular
generation of singlet oxygen was determined using cell permeable DHE (155). Control
group showed a faint background signal compared to ICG conjugated micelles, but
quenching of singlet oxygen with ROS scavenger, sodium azide reduced red
fluorescence (Figure 3.6A). There was concentration dependent increase in SOSG
fluorescence intensity upon irradiation and exhibited 8 fold increase in the fluorescence
intensity at 50 μg compared to the control, but quenching with sodium azide reversed
SOSG fluorescence intensity to background levels (Figure 3.6B), confirming the
specificity of generation of singlet oxygen.
3.3.5 Cell cytotoxicity and cell uptake studies
ICG upon excitation with NIR light at 800 nm generates reactive oxygen species and
local heat. ROS results in lethal DNA and protein damage which leads to cell death.
Cells were exposed to ICG solution and ICG conjugated micelles for 24 h followed by
NIR light exposure at 2W for 2 min. ICG solution caused significant cytotoxicity with 50
% and 5 % cell viability at 8 and 16 μg respectively (Figure 3.7A). Correspondingly,
ICG conjugated micelles were cytotoxic at 30 and 50 μg with 23 and 13 % viability
respectively with no toxicity in ICG micelles alone or laser alone group (Figure 3.7B).
To further study the contribution of PTT and PDT towards cell killing, cells were radiated
at 4 °C or in the presence of 100 mM ROS scavenger sodium azide which blocks the
cytotoxic effect of ROS. Sodium azide completely reversed the cytotoxic effect of ICG
solution at 8 μg but failed to reverse the cytotoxicity at 15 μg. Reversal of PTT effect
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did not alter the cytotoxicity of ICG solution demonstrating PDT as major mechanism of
cell killing. This was further confirmed by partial reversal of cytotoxicity at 15 μg when
both PDT and PTT effect after radiation of ICG solution was blocked. Contrastingly,
PTT effect is the major mechanism of ICG conjugated micelles cytotoxicity as evident
from the reversal of cytotoxicity of ICG micelles upon irradiation at 4 °C. Calcein AM/
Propidium iodide staining was applied to visually evaluate and observe live dead cells
after PT. Fluorescent images corroborated the quantitative findings of MTT assay with
PDT and PTT as major mechanism of cytotoxicity for ICG solution and ICG micelles
respectively (Figure 3.7 C). Moreover, PTT effect alone by ICG micelles does not
completely kill the cells as evident from green viable cells (Figure 5C, NaN3 group).
PTT effect alone only slows down proliferation of cancer cells and it is combination of
PTT and PDT effect that effectively kills cancer cells (Figure 3.7C, micelles).

To

further explain this anomaly in the cytotoxicity mechanism of ICG solution ICG
conjugated micelles, we determined the cellular uptake of ICG in solution and micelle
group using z stacks imaging by confocal microscope. As reported previously for
various nanocarriers, cellular uptake of ICG micelles was by endocytic mechanism
(Figure 3.8D). However, there is significant difference in the cell internalization of ICG
solution and ICG conjugated micelles as shown in orthogonal cell uptake images
(Figure 3.8A & B),. Solution exhibits much higher ICG cellular uptake (green staining)
as compared to ICG conjugated micelles. This finding was affirmed by the quantitatively
measuring the cellular uptake of ICG. Cellular uptake of free ICG was 5 fold higher as
compared to ICG micelles (Figure 3.8C) confirming the confocal images. Cytotoxicity
of ICG was also studied by removing the cell culture medium containing ICG after 24 h
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exposure of ICG solution and ICG conjugated micelles. Absence of ICG in the cell
culture medium did not affect the cytotoxicity of free ICG group as compared to ICG
conjugated micelles (Figure 3.9A).

Removal of ICG conjugated micelles from cell

culture medium completely repealed the phototoxicity of micelles group. These studies
suggest that both solution and micelles group exhibit concentration dependent strong
phototoxicity and intracellular accumulation of ICG solution and ICG conjugated
micelles determine the mechanism of cytotoxicity. ICG micelles also showed time
dependent toxicity with enhanced cell killings upon NIR radiation for longer period of
times (Figure 3.9B).
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Figure 3-5.
Characterization of spectroscopic properties of ICG solution and
ICG conjugated micelles.
(A) Absorption spectrum (B &C) Fluorescence spectrum upon excitation at 640 nm and
760 nm respectively (D) Fluorescence spectrum of polymer ICG conjugate in organic
solvent upon excitation at 760 nm (E) Near infra-red fluorescence image of ICG micelles
with 10 % SDS solution (right) or ICG micelles (left) at 5-100 μg (F) Quantitative
fluorescence measurement of ICG micelles with 10 % SDS solution and ICG conjugated
micelles alone at 12.5 and 100 μg.
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B

Figure 3-6.

Generation of singlet oxygen from ICG conjugated micelles.

(A) Representative fluorescent images of A375 cells treated with ICG conjugated micelles
using DHE staining for singlet oxygen detection at 20 and 50 μg and using NaN3 pretreatment
(800 nm, 2 W, 5 min). (B) Quantitative estimation of generation of singlet oxygen upon radiation
of ICG conjugated micelles in solution using singlet oxygen sensor green. Data are shown as

mean ± SD (n=3)
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Figure 3-7.
Quantitative measurement and assessment of mechanism of
cytotoxicity after NIR radiation.
Cell cytotoxicity of (A) ICG solution and (B) ICG conjugated micelles in A375 cells at 24
h. Data are presented as mean ± SD (n=3) (C) Fluorescent images of live dead staining
after NIR radiation of ICG solution and ICG conjugated micelles in A375 cells alone, in
the presence of 100 mM sodium azide, at 4°C and at 4°C in the presence of 100 mM
sodium azide. Calcein AM stains live cells as green and propidium iodide stains dead
cells as red.
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Figure 3-8.
Cell
quantification.

uptake

study

of

ICG

conjugated

micelles

and

its

Orthogonal projections of confocal sections of cellular uptake of (A) ICG solution and
(B) ICG conjugated micelles showing minimum cellular uptake of ICG micelles at
midpoint of cross sections after 24 h incubation at 37 C. (C) Quantification of cellular
uptake of ICG solution and ICG conjugated micelles after 4, 8 and 24 h incubation of
A375 cells with 20 μg equivalent of ICG. (D) Confocal FL images of A375 cells and
subcellular localization of ICG conjugated micelles after 4 h incubation. Nuclei were
stained with DAPI (blue), lysosomes were stained with Lysotracker (red), green
fluorescence was derived from ICG solution and ICG conjugated micelles and yellow
represents co-localization of lysosomes and ICG.
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Figure 3-9.

Cytotoxicity assay of ICG conjugated micelles.

(A) Quantitative measurement of cytotoxicity of free ICG and ICG conjugated micelles
with replacement of the cell culture medium containing free ICG and ICG micelles after
24 h with fresh medium followed by NIR radiation for 2 min at 2W. (B) Exposure
dependent cytotoxicity of ICG conjugated micelles against A375 cells as analyzed by
MTT assay. A375 cells were incubated with ICG conjugated micelles equivalent to 15
μg for 24 h, followed by 2, 5, and 10 min photoirradiation at 800 nm.
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3.3.6 In vivo and ex vivo NIR imaging
Increase in systemic circulation and enhanced tumor accumulation of ICG
conjugated micelles was confirmed by in vivo whole body NIR fluorescence imaging.
As shown in Figure 3.10A, ICG conjugated micelles demonstrated significantly higher
whole body signal at 24 h due to prolonged circulation and limited renal elimination of
ICG conjugated micelles. In tune with the whole body levels, ICG conjugated micelles
also exhibited enhanced tumor accumulation at 6 and 24 h as compared to ICG solution
(Figure 3.10A). The mean fluorescence intensity of ICG conjugated micelles in tumor
tissue at 24 h is approximately 2.5 fold higher than that of solution (p<<.001). This
increase in tumor accumulated indicated preferential tumor accumulation of ICG
micelles by EPR effect.

In contrast, whole body fluorescence intensity of ICG

conjugated micelles was much lower at 1 and 3 h due to the quenching of ICG signals.
Quenching of the ICG signal confirmed the close packing of ICG within the core of
micelles indicating excellent in vivo kinetic stability of micelles against plasma proteins
and dilution. Organ biodistribution by ex vivo imaging showed that ICG conjugated
micelles efficiently accumulated in the tumor with fluorescence intensity signal
equivalent to highly perfused organ, liver indicating improved tumor accumulation by
EPR effect. Kidney isolated from animal receiving ICG solution have highest
fluorescence signal, signifying rapid renal elimination of ICG and short plasma half-life.
Ex vivo imaging of vital organs reaffirmed the in vivo findings of reduced clearance,
enhanced biodistribution and tumor accumulation of ICG conjugated micelles (Figure
3.10 C&D).
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Figure 3-10.
In vivo NIR fluorescence imaging in A375 subcutaneous
melanoma model.
NIR fluorescence imaging of athymic nude mice of ICG conjugated micelles and ICG
solution at 800 nm spectral channel. (A) Representative image with ellipse indicating
tumor accumulation of ICG. (B) Mean fluorescence signal counts of tumor accumulated
ICG as calculated by ellipse representing region of interest. Data are presented as
mean ± SD (n=5) (C) Ex vivo fluorescent images of peripheral organs 24 h after ICG
injection (D) Mean fluorescence signal counts of major organs of ICG solution and ICG
conjugated micelles group. Data are presented as mean ± SD (n=3)
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3.3.7 Effect of phototherapy on tumor growth
Encouraged by the in vitro efficacy and in vivo NIR fluorescence biodistribution
data, we tested the efficacy of PT of ICG formulations in A375 human melanoma model
in athymic nude mice. After systemic administration of ICG solution and ICG conjugated
micelles, tumors were irradiated with 800 nm laser for 5 min at 2W after 6 h post
injection along with radiation of ICG solution group at 1 h. Mice receiving ICG
conjugated micelles showed complete eradication of the tumor mass next day with no
tumor relapse up to 55 days (Figure 3.11A). Conversely, mice receiving ICG solution
followed by laser irradiation did not exhibit any tumor shrinkage or reduction.. Tumor
growth in ICG solution group did not differ from the control group indicating inefficient
tumor accumulation of ICG for effective phototherapy. To demonstrate the poor efficacy
with ICG solution, irradiation of tumor also was performed at 1 h after the systemic
administration of ICG solution. In this group half of the mice responded with no signs of
tumor relapse upto 9 days whereas half mice showed only slight reduction in tumor
volume with no difference as compared to control at the end of study. It is important to
note that mice did not show any tumor relapse upto 55 days whereas in solution group
(1 h radiation) all mice had tumor at the end of 17 days which suggest significant
improvement in tumor accumulation ICG conjugated by formulation it as ICG conjugated
micelles. Mouse body weight was measured every 2 days to observe any signs of
toxicity due to radiation. Mice receiving radiation did not show any significant drop (less
than 5 % reduction) in the body weight over the course of study indicating that PT was
well tolerated (Figure 3.11B). Post euthanasia, tumors were excised which confirmed
that PT with ICG conjugated micelles completely eradicated the tumor with little
difference between control and ICG solution group (Figure 3.11 C & D).
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Figure 3-11.
model.

D

In vivo efficacy of phototherapy in A375 subcutaneous melanoma

In vivo efficacy of phototherapy in A375 xenograft melanoma model after NIR irradiation
at 800 nm and 2 W for 5 mins, 6 h post i.v. administration. (A) Tumor volume growth
curves of control, ICG solution and ICG conjugated micelles as measured by vernier
calipers. Data are presented as mean ± SD (n=6). (B) Total body weight of tumorbearing mice throughout the course of treatment to observe toxicity. (C) Weight
measurement of excised tumors for all the groups. Data are presented as mean ± SD
(n=6) (D) Representative image of the excised tumor in control, free ICG and ICG
conjugated micelles groups at the end of 17 days.
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3.4 Discussion
Melanoma originated from melanocytes is the most aggressive form of skin cancer
(156). Although systemic chemotherapy remains the mainstay of treating melanoma,
development of resistance and dose limiting toxicity restrict the efficacy of
chemotherapeutics. PT, a combination of inert photosensitizer and light of particular
wavelength has been demonstrated to produce highly cytotoxic effects with little toxicity.
ICG with large safety dose and absorption in the NIR range is an excellent
photosensitizer but with limited vascular extravasation and tumor accumulation.
Numerous nanocarriers have been reported to improve the plasma circulation high life
and tumor accumulation of ICG for phototherapy (157). Saxena et al. reported polymeric
ICG nanoparticles with 350 nm size, ICG loading of 0.20 % w/w and 78% release within
8 hours (149). Liposomes formulation of ICG has also been recently reported with
insignificant improvement of its half-life due to premature ICG release (151). Adsorption
and π-π interaction of ICG with silica nanoparticles and carbon nanotubes have also
been reported respectively (152, 153). However, weak non-covalent interactions
between nanocarriers and ICG could not prevent premature release in vivo and thereby,
could not enhance the peripheral organ distribution. Large particle size, poor loading
and rapid in vivo release are the major limitations of the ICG loaded nanocarriers (158).
Covalent conjugation of ICG derivatives for formulation has been reported previously to
enhance loading and reduce the release but the particle size of these nanoparticles lie
on the upper limit of the preferred size range for in vivo applications (150, 159). In this
study, we have formulated biodegradable ICG conjugated micelles with particle size of
50 nm, increased ICG loading and little premature release for photodynamic therapy of
melanoma. Amphiphilic copolymer with pendant carboxyl groups was synthesized and
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characterized using mPEG as macroinitator. Data from

1

H NMR and GPC

characterization of PEG-MBC and PEG-PCC confirmed the synthesis of copolymer with
desired molecular weight and narrow PDI distribution (Figure 3.3 and 3.4). ICG-NH2 was
conjugated to the pendant carboxyl group using EDC/HOBT coupling chemistry with
conjugation efficiency of around 80% (Figure 3.2). Dodecanol was conjugated to
enhance the hydrophobic interaction as well as to counter negative contribution towards
micelle stability from hydrophilicity and ionic charge of remaining pendant carboxyl
group. Attachment of multiple DC chains facilitated the hydrophobic interaction within
the core of micelles as well as improved the self-assembly of micelles (160).
Micelles prepared by nanoprecipitation were sub 50 nm in size (Figure 3.4) which is
important for efficient tumor penetration by enhanced extravasation and slow tumor
clearance (161, 162). Moreover, the high PEG coverage of ICG conjugated micelles
surface will lead to brush confirmation enhancing the circulatory half-life as well as
stabilization of micelles core (163). Stability of ICG conjugated micelles was also
evident from the strong self-quenching of fluorescent signal as ICG molecules were
closely packed within the core of micelles (Figure 3.5 B & C). Micelles stability was also
studied by partial recovery of ICG fluorescence after addition of SDS as destabilizing
agent (Figure 3.5 E & F). Increase in the ICG fluorescence by SDS indicated that SDS
can disassemble the micelles for enhanced generation of singlet oxygen. Generation of
singlet oxygen upon radiation of ICG conjugated micelles was demonstrated by
observing the fluorescence intensity of SOSG and DHE.
Both ICG conjugated micelles and ICG solution exhibited significant phototoxicity
with distinct mechanism of action (Figure 3.7 A, B & C). PTT effect is the predominant
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mechanism of cytotoxicity by ICG conjugated micelles which can be attributed to the
short half-life of singlet oxygen. Singlet oxygen with a radius of action of around 20 nm
and a half-life of 40 nanoseconds requires deep intracellular penetration of
photosensitizer. However, slow cell uptake of polymeric micelles restricts the uptake of
polymer conjugated photosensitizer. Previously, Xu et al. have shown that polymeric
micelles are not readily taken up by the cells and in case of physical encapsulation,
drug released extracellularly from micelles exhibited rapid cellular uptake (164). Slow
release of covalently conjugated ICG molecules along with slow cellular uptake and
intracellular accumulation of ICG conjugated micelles limited intracellular penetration of
ICG (165-167). Orthogonal images of confocal section of cell uptake studies confirmed
the slow uptake of ICG conjugated micelles with substantial lower intracellular
accumulation of ICG (Figure 3.8 A, B & C).
In vivo biodistribution and enhanced tumor accumulation by EPR effect was studied
by non-invasive NIR fluorescence imaging. Due to quenching of ICG signal, ICG
conjugated micelles exhibited significantly lower signal at 1 and 3 h which is in contrasts
with all the previous reports of ICG loaded nanocarriers (Figure 3.10 A & B). These
reported ICG nanocarriers have shown significant in vitro quenching with little in vivo
quenching of ICG fluorescent signal which suggest premature release of ICG or
disassembly of nanocarriers during circulation (119, 151, 168). In contrast, we observed
significant quenching which confirmed the in vivo stability of micelles for at least 3 h
probably due to the hydrophobic interaction between the DC within the core of micelles.
Such in vivo stability of micelles is prerequisite for their prolonged circulation and tumor
accumulation by EPR effect (169). Although ICG solution showed better in vitro toxicity,
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reduction in tumor volume was negligible which can be attributed to inefficient tumor
accumulation of ICG. Prolonged circulation of ICG conjugated micelles and their marked
tumor accumulation by EPR effect permits marked elevation of tumor temperature and
generation of singlet oxygen which is high enough to ablate the tumor (Figure 3.11 A
and D).
3.5 Conclusion
In this study, we have designed ICG micelles by covalently conjugating ICG-NH2 to
an amphiphillic biocompatible polymer. ICG polymer conjugate self-assembled as 50nm
micelles with excellent in vitro and in vivo stability. ICG conjugated micelles exhibited
photothermal mediated phototoxicity due to limited cellular uptake of micelles. In vivo
NIR fluorescent imaging results showed that the ICG conjugated micelles exhibited
excellent in vivo stability, prolonged circulation and selective accumulation to the tumor
site through the EPR effect. Enhanced accumulation of ICG conjugated micelles
significantly improved the therapeutic efficacy of ICG mediated phototherapy with no
tumor relapse up to 50 days. These results suggest the ICG conjugated micelles have
the can be utilized for phototherapy and imaging of cancer.
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CHAPTER 4 SYSTEMIC DELIVERY OF NANOPARTICLE FORMULATION OF
NOVEL TUBULIN INHIBITOR FOR TREATING METASTATIC MELANOMA*
4.1 Introduction
Melanoma is the fifth most common cancer in the Unites States and its incidence is
increasing by 1.9% annually (170). Due to the high propensity of melanoma for
metastasis to lungs, liver, brain and bones, its treatment remains a challenge and is
associated with the poor survival rate. While surgery and radiation are the first line
therapy for treating localized melanoma, systemic therapy is the cornerstone of clinical
management of metastatic melanoma (1). Currently dacarbazine (DTIC) and kinase
inhibitors are the FDA approved drugs for the treatment of metastatic melanoma. DTIC,
an alkylating agent, exhibits modest efficacy and does not significantly prolong the
survival benefit (171) (less than 5 % complete remission), whereas resistance develops
invariably upon treatment with kinase inhibitors which restricts the prolonged systemic
therapy with these inhibitors (3, 4).
Tubulin inhibitors like vinca alkaloids and taxanes such as paclitaxel have been
clinically prescribed as a single agent or in combination with other chemotherapeutic
agents (5, 172). Encouraged by the clinical utility of tubulin inhibitors, our collaborator
previously reported the synthesis of tubulin inhibitors with antiproliferative IC 50 in
nanomolar range for the treatment of metastatic melanoma (17).
* Adapted with permission. Mundra V, Lu Y, Danquah M, Li W, Miller DD, Mahato RI.
Formulation and characterization of polyester/polycarbonate nanoparticles for delivery
of a novel microtubule destabilizing agent. Pharm Res. 2012; 29(11):3064-74.
*Mundra V, Peng Y, Kumar V, Li W, Miller DD, Mahato RI. Systemic delivery of
nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma. Drug
Deliv Transl Res. 2015;5(3):199-208
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(2-(1H-Indol-5-yl) thiazol- 4-yl) 3, 4, 5-trimethoxyphenyl methanone (LY293), a 5 indole
derivative analog, binds to colchicine binding site and does not exhibit clinically
prevalent drug resistance mechanism such as multidrug resistance (MDR) protein,
breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) (6, 17, 173).
Like paclitaxel, poor aqueous solubility of LY293 necessitates the use of cosolvent
for its systemic delivery (174). Due to poor aqueous solubility, we have previously
administered PEG300 solution of LY293 structure analog through intraperitoneal route
for efficacy studies in lung metastasis melanoma model (174). LY293 dosed at
25 mg/kg showed better lung metastasis inhibition than standard care of therapy DTIC
at 60 mg/kg (Figure 4.1B). In subcutaneous model, after 31 days of treatment LY293
analogues dosed at 25 mg/kg inhibited melanoma tumor growth by 69%; dacarbazine at
60 mg/kg inhibited growth by 52% (Figure 4.1A). However, prolonged administration of
drugs using cosolvents as solubilizing agent is associated with hemolysis and acute
hypersensitivity reactions which require administration of antihistamines and steroids
(175, 176). Additionally, non-specific distribution of tubulin inhibitors like paclitaxel is
associated with dose limiting toxicity of myelosuppression and peripheral neuropathy.
Biodegradable polymeric nanoparticles are attractive formulation strategies for
solubilizing the hydrophobic drug within their core and modulate the drug release (40,
177, 178). Modulation of drug release and preferential accumulation of nanoparticles at
tumor through EPR effect reduces dose limiting toxicity like peripheral neuropathy and
myelosuppression (179, 180). Amphiphillic poly(ethylene glycol) (PEG) based diblock
polyester copolymers of lactide, glycolide and caprolactone have been synthesized for
preparing nanoparticles for delivery of hydrophobic drugs (178). We have previously
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engineered the hydrophobic core of the polyester component of the copolymer into
polyester/polycarbonate component to improve the drug loading of (2-(1H-Indol-5-yl)
thiazol-4-yl) 3, 4, 5-trimethoxyphenyl methanone (LY293) (40, 41).
In this study, we have synthesized mPEG-b-P (CB-co-LA) copolymer for effective
encapsulation of LY293 in nanocarriers as well as for enhanced tumor accumulation
compared to free drug. Synthesized mPEG-b-P (CB-co-LA) diblock random copolymer
of lactide and carbonate was characterized and utilized for nanoparticle formulation of
LY293. Concentration dependent effect of LY293 loaded nanoparticles on cell cycle and
mechanism of apoptosis was studied. Finally, efficacy of LY293 loaded nanoparticles in
syngeneic B16F10 lung metastatic melanoma mouse model was evaluated against
cosolvent solution of LY293.
4.2 Materials and methods
4.2.1 Materials
2, 2-Bis (hydroxymethyl) propionic acid, methoxy poly (ethylene glycol)
(mPEG,Mn = 5000), 8-diazabicycloundec-7-ene (DBU), 1, 5, 7-triazabicyclodecene
(TBD)

benzyl bromide, 2,2-bis(hydroxymethyl) propionic acid and

L-lactide were

purchased from Sigma-Aldrich (St. Louis, MO) and used as received. Dulbecco’s
Modified Eagle Medium (DMEM) medium was purchased from Invitrogen (Carlsbad,
CA). All primary antibodies were purchased from Cell Signaling (Beverly, MA). B16F10
mouse melanoma cell line and A375 human melanoma cell line was acquired from
American Type Culture Collection and no authentication was performed by us. All other
reagents were obtained from Sigma–Aldrich (St. Louis, MO) unless otherwise stated
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and were used as received. Cells were cultured in DMEM supplemented with 10% FBS
(Atlanta Biologicals) and 1% antibiotic/antimycotic mixture (Invitogen).
4.2.2 Synthesis and characterization of LY293
LY293 was synthesized by modifying the A ring of SMART series of analogs(8).
Briefly, tetrahydrofuran (THF) solution of 3, 4, 5-trimethoxybromobenzene (2.47 mmol)
was added to THF solution of n-butyllithium (n-BuLi) (1.6 M, 1.7 mL) under -78 ºC. The
mixture was allowed to stir for 2 h and a solution of Weinreb amide of (R)-N-methoxy-Nmethyl-2-(1-(phenylsulfonyl)-1H-indol-5-yl)-4,5-dihydrothiazole -4-carboxamide

(1.24

mmol) was charged (6). The temperature was allowed to increase to room temperature
(RT) and stirred overnight followed by quenching of reaction mixture with saturated
NH4Cl. Product was extracted with ethyl ether, and dried with MgSO4. Crude product
was refluxed in ethanol solution of 1 N NaOH to obtain the deprotected compound
LY293 which was purified by column chromatography to obtain pure compound as a
light-yellow solid.
4.2.3 Synthesis of mPEG-b-P (CB-co-LA)
Benzyl 2, 2-bis (methylol) propionate was synthesized as reported previously by
reacting 2,2-bis(hydroxymethyl) propionic acid with benzyl bromide at 100°C for 15 h
(40).

Monomer

5-methyl-5-benzyloxycarbonyl-1,

3-dioxane-2-one

(MBC)

was

synthesized by reacting the intermediate with triphosgene at -78°C in pyridine and
dichloromethane. Random MBC and lactide block copolymer (mPEG-b-P (CB-co-LA))
of target molecular weight of 30,000 Da was obtained by ring opening polymerization of
L-lactide and MBC using mPEG as macroinitator and

8-diazabicycloundec-7-ene

(DBU) (2.5 mol relative to mPEG) catalyst (181, 182). Reaction was carried out in DCM
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at room temperature for 6 h, after which benzoic acid was added to quench the catalyst.
The resulting solution was concentrated to approximately 50% of the initial volume and
added dropwise into excess of cold isopropanol for polymer precipitation. Following
synthesis, the copolymer was characterized by 1H NMR and GPC.

For 1H NMR,

chemical shifts were calibrated using tetramethylsilane as reference and reported as
parts per million. The molecular weight and polydispersity index (PDI) of mPEG-b-P
(CB-co-LA) polymers were determined by GPC using a Shimadzu GPC system
equipped with a Styragel HR 4E GPC column and a differential refractive index
detector. Dimethyl formamide (DMF) was used as an eluent at a flow rate of 0.5 mL/min.
Narrow PEG standards (5,800-71,700 g/mol) from American polymer standards corp
were used for generating standard curves and the data was processed using LC
Solution ver.1.21 GPC option software.
4.2.4 Preparation and characterization of nanoparticles
Blank and LY293 loaded nanoparticles were prepared by o/w emulsification
using 1% polyvinyl alcohol as an emulsifier (41). mPEG-b-P (CB-co-LA) and drug
dissolved in dichloromethane and acetone mixture (1:1 ratio) were emulsified using a
Misonix ultrasonic liquid processor (Farmingdale, NY) at amplitude of 20 for 2 min.
Organic phase was removed by a rotavapor to obtain stabilized nanoparticles and
concentrated by ultracentrifugation at 20,000 rpm for 30 min followed by washing with
water to remove polyvinyl alcohol and unentrapped drug. Mean particle diameter and
size distribution of drug-loaded nanoparticles were determined via dynamic light
scattering (DLS) using a Malvern Zetasizer Nano Series (Worcestershire, UK). Surface
morphology and particle size of nanoparticles was determined using a transmission
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electron microscope (TEM) (JEM-100S Japan). Suspension of nanoparticles on a
copper grid was negatively stained with NanoVan®. The grid was visualized at 60 kV
with magnifications ranging from 50, 000X to 100,000X.
Drug loading was estimated by reverse phase high performance liquid
chromatography (RP-HPLC, Shimadzu) at 290 nm wavelength using a C18 column
(250 mm x 4.6 mm, Alltech, Deerfield, IL). Mobile phase composed of 65:35 V/V of
acetonitrile and water was used. LY293 concentration was calculated using the peak
area from a standard curve with R2=0.9987 and lower quantification limit of 73.42 ng/ml.
Drug loading was determined by the following formula
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔

𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 = 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑋 100
4.2.5 In vitro drug release from nanoparticles
Dialysis technique was employed to determine the drug release from mPEG-b-P
(CB-co-LA) nanoparticles. mPEG-b-P (CB-co-LA) nanoparticles were placed in a
dialysis membrane of 8,000 Dalton cut-off and dialyzed against 50 mL of 0.1 % Tween
80 phosphate buffered saline (PBS) (pH 7.2) in a thermo-controlled shaker with a
stirring speed of 180 rpm. Samples of 1 mL were withdrawn at specified times (4, 8, 12,
24, 36, 48, 72, 96, 120, 168 and 216 h) and replaced with fresh media.

Release

samples were assayed using RP-HPLC as described for drug loading estimation. The
cumulative amount of drug released into the media at each time point was evaluated as
the percentage of total drug release to the initial amount of the drug. All experiments
were performed in triplicate and the data is reported as the mean of the three individual
experiments.
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4.2.6 Cell cytotoxicity assay
A375 and B16F10 cells were cultured in DMEM media supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic–antimycotic at 37°C in humidified environment of
5% CO2. Cells were seeded overnight in 24 well plates at a density of 25,000 cells per
well and thereafter treated with DMSO solution of LY293 and LY293 loaded
nanoparticles for 72 h. At the end of 72 h, cell culture medium was replaced with 50 μL
of 5 mg/mL 3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)
solution and incubated for 3 h at 37°C. Cell culture medium was removed and formazan
crystals were dissolved in 500 μL of DMSO for measuring the absorbance. Absorbance
was measured by a microplate reader at a wavelength of 560 nm. Cell viability was
expressed as the percentage of the control group. DMSO control and blank
nanoparticles were included in all experiments.
4.2.7 Propidium iodide staining and cell cycle analysis
A375 and B16F10 cells were cultured overnight in a 6 well plate followed by
thymidine blockade for 12 h. Cells were then incubated with LY293 loaded
nanoparticles for 48 h. Treated cells were trypsinized and fixed in 90% ice-cold ethanol
overnight. After washing with PBS containing RNase (1 mg/mL), cell pellet was resuspended in 5 μg/mL propidium iodide staining solution for 30 min at the room
temperature. Cell cycle distribution was measured by flow cytometry (Becton,
Dickinson, NJ, USA). Results from 10,000 fluorescent events were obtained for cell
cycle analysis.
4.2.8 Western Blot Analysis
A375 cells cultured overnight in a 12 well plate were treated with LY293 for 24 h.
Subsequently, cells were lysed using RIPA buffer (Sigma- Aldrich, St. Louis, MO) and
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protein concentration was measured with bicinchoninic acid (BCA) protein assay kit
(Pierce, Rockford, IL). The lysate was boiled for 5 min, subjected to a 15 % SDS-PAGE
and transferred to a PVDF membrane using iBlot™ system (Invitrogen, Carlsbad, CA).
Membranes were blocked with 3% BSA in 1x Tris buffered saline (TBS) at room
temperature for 1h and then incubated with primary antibodies at 4 °C overnight,
followed by incubation with anti-goat or anti-rabbit IRDye 800CW secondary antibodies
for 1h at room temperature. All the blots were re-probed with total β-actin antibody as
control. The signal of target proteins was detected Li-COR Odyssey® infrared imaging
system (Li-COR, Lincoln, NE).
4.2.9 Calcein acetoxymethylester (Calcein AM) assay and cell cytotoxicity assay
in Pgp overexpressing melanoma cell lines
MDA-MB435 and MDA-MB435/LCC6 MDR1 cells were seeded into black wall
clear bottom 96 well plates at a density of 50,000 cells per well a day before the
experiment. Media was removed and cells were washed twice with PBS. After treating
cells with various concentrations of test compounds in 50 μL of PBS for 15 min at 37°C,
50 μL calcein AM (10 μM) in PBS was added to each well and incubated at 37°C for
additional 15 min. Fluorescent intensity was determined using a SpectraMax M2/M2e
spectrofluorometer (Sunnyvale, CA) at the excitation wavelength of 485 nm and
emission wavelength of 525 nm.
Cytotoxic or antiproliferative activity of LY293 analogues (ABI270) was
investigated by our collaborator in MDA-MB435 and MDA-MB435/LCC6 MDR1 by using
the sulforhodamine B (SRB) assay. Cultured cells were plated in 96-well plates and
incubated with titration of the test compounds. The cells were stained with SRB after
96 h treatment
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4.2.10 In vivo anticancer efficacy study
All animal experiments were performed in accordance with the NIH animal use
guidelines and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Nebraska Medical Center (UNMC, Omaha, NE). Lung
metastasis in C57/BL6 mice (6−8 weeks old, weight around 20 g) was used as a tumor
model. Mice were injected intravenously with 100 μL of B16F10 cell suspension
containing 105 cells through tail vein. Post one week, mice were divided into three
groups (n =6): control, LY293 in 35 % of cosolvent (composed of propylene glycol,
cremophor EL and ethanol (50:30:20 ratio) and 65 % of dextrose solution and LY293
loaded nanoparticles. Formulations were injected into the tail vein of mice thrice a week
at the dose of 15 mg/kg. Mice were sacrificed at the end of the treatment, and lungs
were separated and expanded with 10% formalin buffer. The number of lung metastasis
nodules was noted and tumor index was calculated using formula 1*a + 2*b + 3*c where
a is the number of nodules with size <1 mm; b is the number of nodules with size
between 1 and 2 mm; and c is number of nodules with size >2 mm. Animal mobility and
body weight were monitored during the entire experiment period to assess any toxicity.
In addition, tumor tissues were fixed in formalin buffer and sections were stained with
hematoxylin and eosin (H&E). For immunohistochemistry (IHC) analysis, sections of
5−7 μm thickness were cut and immunostained with rabbit anti-Caspase-3, anti-Ki67
and anti-S100 primary antibodies, respectively. The immunoreactivity was detected
using goat anti-rabbit IgG, H&L chain specific peroxidase conjugate and subsequent
incubation with DAB substrate.
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4.2.11 Statistical analysis
Statistical significance of the difference between the two groups was determined
by an unpaired Student’s t-test and between several groups by one-way analysis of
variance.
4.3 Results
4.3.1 Synthesis and characterization of LY293
LY293 was synthesized by Dr. Yan Lu as shown in Figure 4.2A and the
chemical structure of synthesized LY293 was ascertained by 1H NMR (Figure 4.2B),
and ESI-MS.

H NMR (300M, CDCl3)  8.36 (br, s, 1 H), 8.31 (s, 1 H), 8.21 (s, 1 H),

1

7.89 (dd, 1 H, J = 1.8, 2.7 Hz), 7.46 (d, 1 H), 7.62 (s, 2 H, J = 8.7 Hz), 7.29 (t, 1 H, J =
2.7 Hz), 6.64 (br, 1 H), 3.95 (s, 6 H), 3.89 (s, 3 H). MS (ESI) had m/z ratio of 417.1 (M +
Na) + and 392.9 (M - H)-.
4.3.2 Synthesis and characterization of mPEG-b-P(CB-co-LA)
DBU, an organic base with low nucleophilicity and mPEG as macroinitator was
utilized for synthesis of mPEG-b-P(CB-co-LA) copolymer in solution at ambient
temperature with high conversion rate. Synthesized mPEG-b-P(CB-co-LA) copolymer
was characterized by 1H NMR and GPC.

1

H NMR spectra was used to confirm the

polymerization and calculation of molecular weight of the copolymer (Figure 4.3A). The
emergence of the multiplet peak at δ: 4.25–4.35 ppm, δ: 7.3 ppm from the carbonate
monomer and one methylene proton of lactide at δ= 5.12 ppm confirms the successful
ring opening polymerization and formation of mPEG-b-P(CB-co-LA) copolymers. The
relative molecular weight of the LA and MBC block was estimated based on the peak
areas of three fifth of the 5.12 ppm signal and the five protons associated with the
phenyl ring in the carbonate monomer at 7.3 ppm. From 1H NMR, calculated molecular
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weight of mPEG-b-P(CB-co-LA) was 31200 with 90 % conversion rate for LA and 60 %
conversion rate for MBC (Figure 4.3C). As PEG was used as a macroinitator for ring
opening polymerization, narrow PEG standards (5,800, 10,225, 14,500, 20000, 31,380,
50,450 and 71,700 g/mol) were used to generate standard curve for GPC analysis. We
characterized mPEG-b-P(CB-co-LA) copolymer by GPC, which indicated a narrow
molecular weight distribution with a PDI of 1.20 (Figure 4.3 C & B). The molecular
weight values determined by GPC were 29671 for weight average molecular weight
(Mw) and 24650 for number average molecular weight (Mn). NMR and GPC data
confirmed the synthesis of copolymer with controlled molecular weight with narrow
molecular weight distribution.
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A

B

C

Figure 4-1.
In vivo efficacy study of LY293 analog, ABI compounds in
xenografted human A375 model and in B16-F10 melanoma lung metastasis model
(A) LY293 analog, ABI-288 treatment inhibited xenografted human A375 melanoma
tumor growth on SHO mice. Tumor growth curves (n = 5 per group). Treatment was i.p.
injection once daily for 31 days. (B) ABIs and DTIC treatment inhibited B16-F10
melanoma cell metastasis to lungs of C57BL/6 mice after tail vein inoculation.
Representative photos of lungs with melanoma nodules (black dots) on them (n = 8 per
group). Treatment was i.p. injection 5 days/week for 2 weeks. (C) Number of melanoma
nodules on each lung. Points: individual nodule number; long line in the middle: mean;
short line on the top and bottom: 95 % confidence intervals. (Adapted from Ref 174)
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Figure 4-2.
Synthesis and characterization of (2-(1H-Indol-5-yl) thiazol- 4-yl) 3,
4, 5-trimethoxyphenyl methanone (LY293).
(A) Synthesis scheme of LY293. (B) 1H NMR spectrum of LY293
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(A) 1H NMR spectrum of mPEG-b-P(CB-co-LA) in DMSO-d6 and chemical structure of
mPEG-b-P(CB-co-LA) copolymer. (B) Representative GPC chromatogram of mPEG-bP(CB-co-LA). (C) Characterization of mPEG-b-P (CB-co-LA) copolymer by GPC for
molecular weight and polydispersity index. Mw and Mn weight and number average
molecular weights respectively as determined by GPC; PDI (Mw/Mn).
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4.3.3 Formulation, characterization and in vitro cytotoxicity of nanoparticles
The mean particle size of mPEG-b-P(CB-co-LA) nanoparticles was 150 nm with a
PDI of 0.068 as determined by DLS (Figure 4.4A). Drug loading and ultracentrifugation
did not alter the particle size and its uniform distribution. TEM confirmed the uniform
spherical particle of 50-70nm (Figure 4.5B). Drug loading calculated by HPLC was 2.5,
4.11 and 7.40 % at the theoretical loadings of 2.5, 5 and 10 %, respectively (Figure 4.4
C). The cumulative percentage of LY293 released from mPEG-b-P (CB-co-LA)
nanoparticles with two different drug loadings is shown in Figure 4.5. These
nanoparticles did not show any burst release and less than 10 % of drug was released
after 10 h (13). Absence of burst release indicated excellent encapsulation of the drug
within the nanoparticles and miscibility of drug within the polymeric core. However, 5 %
drug loaded nanoparticles showed a faster drug release as compared to 2.5 %
nanoparticles. Similarity factor (f2) was calculated to compare the drug release profiles
of 2.5 and 5 % drug loaded nanoparticles. The similarity factor was 41.16 for (2.5 vs. 5
% NP) indicating nanoparticles with two different drug loadings showed different release
profiles as the release profiles are considered different when the similarity factor is less
than 50.
LY293 loaded nanoparticles inhibited the cancer cell proliferation as efficiently as
DMSO solution of LY293 with an IC50 of 17.5 nM in A375 and B16F10 cells (Figure
4.6). Blank nanoparticles did not elicit any cytotoxicity to the cells as expected with
biodegradable polymers.
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Figure 4-4.
Characterization of nanoparticle for size distribution, morphology
and drug loading.
(A) Dynamic light scattering histogram; and (B) transmission electron micrograph
obtained negative staining. (C) Effect of theoretical loading on particle size and loading
efficiency
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Figure 4-5.

In vitro drug release from mPEG-b-P(CB-LA) nanoparticles.

In vitro release of LY293 of 2.5 and 5 % loaded mPEG-b-P(CB-co-LA) nanoparticles.
Results are expressed as the mean ± SD (n = 3).
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Figure 4-6.
Cell cytotoxicity of DMSO solution of LY293 and LY293 loaded
nanoparticles.
(A) A375 and (B) B16F10 cell death after 72h of treatment. Cytotoxicity was determined
by MTT Assay and expressed as % of control. Blank nanoparticles used as control for
LY293 loaded nanoparticles group. Results are expressed as the mean ± SD (n = 4).
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4.3.4 Effect of LY293 loaded mPEG-b-P(CB-co-LA) nanoparticles on cell cycle
and apoptosis
Tubulin polymerization inhibitors bind to tubulin and arrest the cell cycle in G2/M
phase. As shown in Figure. 4.7 A&B, 48h treatment of A375 and B16F10 cells with
LY293 loaded nanoparticles led to cell cycle arrest in G2/M phase while no effect was
observed upon treatment with blank nanoparticles. Anti-mitotic activities of LY293
resulted in significant increase in G2/M phase from 14.13±0.60 % in the control group to
54.33±0.085% and 76.19±0.94 % at 15 nM and 250 nM of LY293 loaded nanoparticles
group in A375 (p< 0.005).
Disruption of the cell cycle progression and arrest of cells in G2/M activates
apoptotic cell mechanism. Treatment with LY293 loaded nanoparticles significantly
increased the protein levels of cleaved PARP with a corresponding decrease in the
levels of total PARP levels (Figure 4.7C). In addition, the cells in sub G1 phase were
also increased from 2.005±0.25% in control to 28.35±0.92 % and 41.9±1.76% for 48 h
at 15 and 250 nM, respectively (p<0.005). The increase of cell population in sub G1
phase indicated that apoptotic cells were increased as LY293 loaded nanoparticle
treatment arrested cells in G2/M phase (Figure 4.7 D).
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Figure 4-7.
Concentration dependent effect of LY293 loaded nanoparticles on
cell cycle distribution.
Cells were treated with LY293 loaded nanoparticles (15 and 250 nM) for 48 h, stained
with propidium iodide and analyzed on a flow cytometer (A) B16F10 (B) A375. Results
are expressed as the mean ± SD (n=3). ***p<0.0005 for cells in G2/M phase using
Student’s unpaired t test. (C) A375 were treated with LY293 loaded nanoparticles at 15
and 20 nm, protein was isolated at 24h. Total and cleaved PARP expression at protein
level was determined using Western blot. Representative beta actin blot is shown. (D)
A375 cells were treated with LY293 loaded nanoparticles for 24 h and quantitative
analysis of apoptotic cells as determined by staining with propidium iodide and analyzed
on a flow cytometer. Results are expressed as the mean ± SD (n=3). **p<0.005 using
Student’s unpaired t test.
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4.3.5 Effect of LY293 on Pgp activity
To determine the inhibitory activity of LY293 on Pgp, intracellular level of calcein AM
(viability dye) was measured by fluorescence spectroscopy. Pgp overexpressing MDAMB435/LCC6 MDR1 cells were treated with Verapamil, LY293 and paclitaxel.
Verapamil is a well-known inhibitor of Pgp activity and leads to intra cellular
accumulation of calcein AM. LY293 lead to significant intra cellular accumulation of
calcein AM at a concentration of 5 and 50 µM as compared to untreated and paclitaxel
treated cells (Figure 4.8).
4.3.6 In vivo efficacy study
Melanoma is highly metastatic, and lung is one of the major target organs for
metastasis. We used an experimental lung metastasis mouse model established via tail
vein injection of melanoma cells to test the efficacy of LY293 loaded nanoparticles in
preventing tumor lung metastasis. After 2 weeks of experimental treatment, the tumor
index was 84, 38, and 30 in control, the cosolvent solution of LY293 and LY293 loaded
nanoparticle groups, respectively (Figure 4.9A). Tumor index was significantly different
between the control and LY293 loaded nanoparticle treated groups (p<0.00005).
Treatment with LY293 significantly reduced the nodule count and black cellular mass
associated with the lungs (Figure 4.9A). H&E staining of lung tissue confirmed the
inhibition of proliferation of metastatic cells. In the control group, normal lung
parenchyma was not visible and was completely covered with the dense metastatic
tissue. Significant inhibition of proliferation of melanoma cells by LY293 loaded
nanoparticle treatment group was further confirmed by the reduced density of S100
immunostains (Figure 4.10). Ki67 positive staining showed significant proliferation in
control group as compared to LY293 treated group. We observed the reduction in body
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weight across all groups including control after treatment started. There was statistical
difference for reduction in body weight between the control and LY293 loaded
nanoparticle treatment group (p<0.05). Systemic administration of LY293 loaded
nanoparticles and cosolvents did not exhibit any toxicity which was confirmed by the
absence of necrosis or inflammation in H&E staining of liver and kidney sections
(Figure 4.10).

88

A

B

C

Figure 4-8.
Effect of LY293 on Pgp activity and cell cytotoxicity in
resistant melanoma cell line (MDR cell) and the matching sensitive parent cell
line.
(A) Intracellular calcein accumulation in MDA-MB435/LCC6MDR1 after 30 min
treatment with Verapamil, LY293 and PTX. Results are expressed as the mean ± SE
(n=3). (B) Fluorescent images depicting dose-dependent increase in intracellular
calcein fluorescence in MDA-MB435/LCC6 MDR1 following 30 min treatment with
LY293. (C) In vitro growth inhibitory effects of the ABI compounds in comparison to
other anticancer drugs on multidrug-resistant melanoma cell line (MDR cell) and the
matching sensitive parent cell line (Normal Melanoma cell). Resistance indexes were
calculated by dividing IC50 values on multidrug-resistant cell line MDA-MB435/LCC6MDR1 by IC50 values on the matching sensitive parental cell line MDA-MB435. (Adapted from Ref 174)
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Figure 4-9.
Effect of systemic therapy of LY293 cosolvent solution and LY293
loaded nanoparticles on proliferation of lung metastasized melanoma.
(A) Tumor index in B16F10 lung metastasis mouse melanoma model at three weeks
after intravenous injection of different formulations. ***p<0.00005 using Student’s
unpaired t test. (B) Change in body weight in of mice at the end of the study. Results
are presented as mean ± SD (n = 6). (C) Representative photos of lungs with melanoma
nodules (black dots) on them (C) H&E stained images of treated group showed normal
lung parenchyma with limited mass of metastatic growth (arrow) as compared to dense
metastatic tissue in the control group (Solid arrow). Black bar represents 200 μm.
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Figure 4-10.
Ki67.

Immunohistochemistry staining of isolated lungs for S100 and

Representative IHC images for S100 and Ki67 staining of lung tissue sections after 2
weeks of treatment. White bar represents 200 μm. H&E staining of liver and kidney
confirmed the absence of nanoparticle toxicity to vital organs.
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4.4 Discussion
Prognosis of metastatic melanoma is poor and associated with a survival rate of less
than 15 % at the end of five years (170, 183). Inherent ability of melanocytes to survive
under duress as well as the development of resistance to cytotoxic drugs remains key
challenges for poor prognosis of metastatic melanoma (184). For the last three decades
since its initial FDA approval, dacarbazine remains the standard care of therapy for
metastatic melanoma. However, treatment with dacarbazine leads to the development
of resistance and has a poor response rate of approximately 7.5% (1). In spite of the
clinical potential of paclitaxel and other tubulin inhibitors, ATP dependent efflux of these
drugs by transporters contributes to the development of resistance (185, 186). To
overcome MDR resistance and enhance the efficacy, we have previously synthesized
potent tubulin inhibitor, phenyl thiazole (PAT) analogs with identical nanomolar efficacy
in both parent and MDR overexpressing resistant cell lines (6). Although calcein AM
efflux assay suggested that LY293 is a Pgp substrate (41) and should not have identical
IC50 in MDR overexpressing cell lines, this anomaly can be attributed to the excellent
permeability (33 x 10-6 cm/s) of LY293 analogs (187). Unlike paclitaxel, vinblastine and
colchicine, LY293 has very high permeability and efflux by Pgp does not limit its
intracellular accumulation (188, 189).
In addition to MDR resistance, poor solubility and non-specific distribution of tubulin
inhibitors leading to the dose limiting toxicity are barriers for their systemic delivery.
Nanodelivery systems have been designed to solubilize the poorly soluble drug and for
effective tumor accumulation of drug through EPR effect. Enhanced tumor accumulation
of nanoparticles will reduce the peripheral exposure and associated toxicity like
peripheral neuropathy and myelosuppression. Herein, we have synthesized random
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diblock copolymer of PEG block and block comprised of carbonate and lactide for
systemic delivery of LY293. This copolymer consisted of mPEG (5000 Dalton) block that
forms hydrophilic outer shell while the hydrophobic core is composed of lactide and
carbonate. Previously, we have shown that modification of the core with carbonate
monomer improved drug encapsulation and its release from nanocarriers (40). We have
synthesized mPEG-b-P(CB-co-LA) copolymer by ring opening polymerization (ROP) of
lactide and MBC using hydroxyl group of mPEG with N heterocyclic carbenes (NHCs).
NHCs are strong organic bases, which allow ROP in solution at room temperature. For
the synthesis of polymer of desired molecular weight with low PDI, two different NHCs,
DBU and TBD at molar ratios of 1, 2.5 and 5 relative to mPEG were utilized. Based on
the GPC and NMR data (Figure 4.3), we found that DBU at 2.5 molar ratio for 6 h were
the optimum reactions conditions. With TBD, we could synthesize the polymer of
desired molecular weight but PDI was higher as compared to DBU catalyst. This can be
attributed to the higher basicity of TBD which makes it highly reactive leading to
transesterification and backbiting side reaction (190). Nederberg et al have reported
ROP of lactide and carbonate monomer of desired degree of polymerization using 1
molar of DBU (181, 182). This difference in the molar ratio of a catalyst can be
attributed to the initiator used for ROP and the targeted molecular weight of the
polymer.
Nanoparticles were formulated by film evaporation, dialysis, nanoprecipitation and
o/w

emulsification

method.

However,

nanoparticles

formulated

only

by

o/w

emulsification method had acceptable size and drug loading. We were able to
encapsulate LY293 with high efficiency (Figure 4.4), which can be attributed to the
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ability of the hydrophobic core to solubilize LY293. In addition to the appreciable drug
loading, the hydrophilic mPEG shell could prevent the aggregation by steric hindrance
and possibly reduce uptake by the reticuloendothelial system (RES) for longer blood
circulation (191). We observed that an increase in initial drug loading led to decrease in
the encapsulation efficiency of LY293 which can be attributed to the limited holding
capacity of the hydrophobic core, reaching saturation at higher initial drug loading with a
subsequent decrease in LY293 encapsulation (Figure 4.4 C).
In vitro cytotoxicity of LY293 loaded nanoparticles showed no loss of LY293 activity
upon its formulation as nanoparticles against melanoma cancer cell lines (Figure 4.6).
As a microtubule polymerization inhibitor, LY293 exerts its antiproliferative effect by
targeting and destabilizing microtubules. The cell cycle analysis indicated that after
treatment with LY293 loaded nanoparticles. LY293 loaded nanoparticles led to the
concentration dependent arrest of A375 and B16F10 cells in G2/M phase (Figure 4.7).
Tubulin polymerization is essential for rapid proliferation of cancer cells by mitotic
division and the inhibition of tubulin polymerization results in the activation of intrinsic
apoptotic pathway. Cell cycle analysis confirmed that the anticancer mechanism of
LY293 is through the arrest of cell cycle in G2/M phase and subsequent activation of
intrinsic apoptotic cellular machinery. In addition, LY293 loaded nanoparticle treatment
resulted in significant increase in fraction of cells in sub-G1 phase (Figure 4.7). This
increase in cell population in sub-G1 phase indicated the fraction of cells undergoing
DNA damage and apoptosis by LY293 loaded nanoparticles.
After demonstrating excellent efficacy of LY293 loaded nanoparticles against
melanoma cell lines, we tested the in vivo efficacy of LY293 loaded nanoparticles in
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syngeneic B16F10 lung metastasis mouse model, which is an extremely aggressive
metastatic model. Tumor burden as well as H&E data clearly showed that LY293 loaded
nanoparticles inhibited the proliferation of metastatic B16F10 nodules (Figure 4.9).
However, there was no significant difference between cosolvent solution and LY293
loaded nanoparticles, which can be attributed to premature release of the encapsulated
drug from the nanoparticle core. Rapid diffusion of the encapsulated drug across the
hydrophobic core led to premature release during circulation and did not significantly
alter the distribution of LY293 towards tumor. To minimize the premature drug release
and further improve the tumor accumulation, polymeric drug conjugates have improved
stability in the circulation with enhanced tumor accumulation. For future studies, we plan
to redesign the polymeric nanocarriers for allowing chemical conjugation of the drug
analogs for preferential tumor accumulation and reduction of peripheral toxicity on
systemic administration.
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Chapter 5 GENETICALLY MODIFIED HUMAN BONE MARROW DERIVED
MESENCHYMAL STEM CELLS FOR IMPROVING THE OUTCOME OF HUMAN
ISLET TRANSPLANTATION*
5.1 Introduction
Type I diabetes is an autoimmune disease characterized by the destruction of islets.
Transplantation of human islets has been clinically used to achieve insulin
independence. However, in addition to long term graft rejection, clinical success of islet
transplantation is limited by primary non-function (PNF) of islets (192). PNF is
characterized by poor glycemic response due to β-cell death in the first two weeks after
transplantation (193). There is marked β-cell death immediately after transplantation
due to hypoxia and exposure to inflammatory cytokines released by infiltrating immune
cells (194). Human islets upon exposure to inflammatory cytokines show increased
expression of apoptosis markers (195). Interleukin -1 beta (IL-1β) produced by islets
and macrophages plays a key role in the islet apoptosis after transplantation (196). hIL1Ra competitively blocks IL-1β binding and has been shown to minimize the detrimental

effect of IL-1β on islet viability (196, 197) .
Islets in pancreas have dense network of capillaries, much higher as compared to
surrounding exocrine tissues (198, 199). Besides rich blood supply, there is an
endothelial endocrine axis within adult pancreas, which is essential for the proliferation
of β cells (200). Islet isolation and purification process not only destroys external
vasculature but also adversely affects the intra islet endothelial cells (201).
Revascularization of islet grafts is an essential event for the success of islet
transplantation (202).
*Mundra V, Wu H, Mahato RI. Genetically Modified Human Bone Marrow Derived
Mesenchymal Stem Cells for Improving the Outcome of Human Islet Transplantation.
PLos One. 2013; 8(10): e77591
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It has been demonstrated that vascular endothelial growth factor (VEGF) stimulates
angiogenic capacity of intra islet endothelial cells and also recruits recipient endothelial
cells to form new micro vessels (203, 204).
We previously demonstrated that bicistronic adenoviral vector encoding hVEGF and
hIL-1Ra can improve the viability and revascularization of transplanted islets (7).
However, adenovirus transduction of islets results in immune response especially when
relatively higher multiplicity of infection (MOI) is used to get desired transgene
expression (9, 196). To resolve this potential issue, we have used human bone marrow
mesenchymal stem cells (hBMSCs) as gene delivery vehicles. In addition, hBMSCs
also provide immune and anti-inflammatory protection to islet grafts (205) .
In this report, we have shown that hBMSCs were transduced with bicistronic
adenoviral vector to coerexpress hVEGF and hIL-1Ra. The effect of Adv-hVEGF-hIL1Ra transduced hBMSCs on islet viability and glucose stimulation was determined.
Islets were co-transplanted with transduced hBMSCs under the kidney capsule of
diabetic NSG mice to determine the effect of stem cells and gene therapy on the
glycemic control and revascularization of transplanted islets.
5.2 Materials and methods
5.2.1 Materials
Replication-deficient (ΔE1/ΔE3) Adv-hVEGF-hIL-1Ra containing a cytomegalovirus
(CMV) promoter, hVEGF cDNA, and rabbit β-globin poly A in the E-1 region, and a CMV
promoter, hIL-1Ra cDNA, and rabbit β-globin poly A in the E-3 region was constructed
amplified, and the titer was measured in our laboratory as previously described (206).
Primary hBMSCs, HyClone Advanced Stem Cell Medium and Medium Supplement
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were purchased from Thermo Fisher Scientific (Waltham, MA). Human islets were
received from Integrated Islet Distribution Program (Duarte, CA). CMRL-1066 medium
for islet culture, propidium iodide (PI) and 6- diamidino-2-phenylindole (DAPI) were
purchased from Sigma Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was
purchased from MediaTech Cellgro (Herndon, VA). Phosphate-buffered saline (PBS)
was purchased from GIBCO-BRL (Gaithersburg, MD). hVEGF and hIL-1Ra ELISA kits
and recombinant inflammatory cytokines (IL-1β, TNF-α and IFN-) were purchased from
R&D Systems (Minneapolis, MN). Human insulin and c-peptide ELISA kits were
purchased from Alpco Diagnostics (Windham, NH). The primary antibodies for human
insulin, human von-willebrand factor (vWF), and the Dylight 488-conjugated secondary
antibody were purchased from Abcam (Cambridge, MA). Alexa Fluor 568- conjugated
secondary antibody and 0.25% trypsin were purchased from Invitrogen (Carlsbad, CA).
Eight-well Lab Tek Chamber slides were purchased from Nalge Nunc. (Rochester, NY).
Ultrasensitive One Touch glucose test strips and One Touch Ultra glucometer were
purchased from LifeScan (Milpitas, CA). Tissue-Tek optimal cutting temperature
(O.C.T.) compounds were purchased from Sakura Finetek (Torrance, CA).
5.2.2 Characterization, transduction and differentiation of hBMSCs
Fluorochrome-coupled antibodies specific for Stro-1, CD73, CD90, CD105 and
CD146 were used to analyze surface markers. Flow cytometric data were acquired
using LSR II Special Option Flow Cytometer (BD Biosciences) and analyzed using
FACSDiva software (BD Biosciences).
hBMSCs were plated at a density of 0.2 million cells in 6 well plates for 24 h and
transduced with Adv-hVEGF-hIL-1Ra for 3 h at MOIs of 100 and 200. hBMSCs were
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then washed thrice with PBS and subsequently cultured for 10 days. Cell culture media
was collected every two days to estimate the expression of hVEGF and hIL-1Ra by
ELISA. Total cellular RNA was isolated using an RNeasy mini kit (Qiagen, Valencia,
CA) and the extracted RNA (1 μg) was reverse transcribed to generate the first strand
cDNA. Two microliters of cDNA were used as a template and analyzed by SYBR
Green-I dye universal PCR master mix on a LightCycler 480 Instrument. To assess the
speciﬁcity of the ampliﬁed PCR product, melting curve analysis was performed on a
LightCycler 480 Instrument. The results of stem cell markers (Nanog and Oct4) mRNA
levels were compared by calculating the cross point value and normalized for GAPDH
reference gene.
To determine the effect of Adv-hVEGF-hIL-1Ra transduction on hBMSCs
differentiation, hBMSCs were cultured in MEM alpha media containing 10% FBS, 1%
antibiotics (streptopmycin + penicillin), 1 µM dexamethasone, 0.5 mM 3-isobutyl- 1methylxanthine, 0.2 mM indomethacin and 10 µg/ml insulin after transduction at 200
MOI for 3 h. Adipogenic differentiation media was replaced every 3–4 days for two
weeks. Adipogenic differentiation of hBMSCs was assessed using Oil Red staining. For
osteogenic differentiation, transduced hBMSCs were incubated at 50-70 percent
confluence in MEM alpha media containing 10 M dexamethasone, 0.2 mM ascorbic acid
mM and β-glycerolphosphate. The medium was replaced every 3–4 days for 21 days
before fixing and Alizarin Red S staining.
5.2.3 Islet viability study
After transduction with Adv-hVEGF-hIL-1Ra at 200 MOI for 3 h, 5×105 hBMSCs
were trypsinized (0.25%) and co-cultured with 500 IEs in a 10 cm dish of CMRL-1066
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medium with 10% FBS for 2 days. The islet/hBMSCs co-culture was stimulated with
cytokine cocktail (5 ng/ml IL-1β, 10 ng/ml TNF-α and 50 ng/ml IFN-γ) for 10 days and
stained with 5 μg/ml calcein-AM and 2 μg/ ml propidium iodide for 30 min to assess islet
viability under a fluorescent microscope.
Insulin production of human islets was quantified by the static insulin release
method. Briefly, 500 IEs were cultured alone or with 5×10 5 untransduced or with 5×105
Adv-hVEGF-IL-1Ra transduced hBMSCs (200 MOI) in a 10 cm dish containing CMRL1066 medium with 10% FBS for 10 days. Cytokine cocktail was added on day 2 and the
islet/hBMSC co-culture was incubated with cytokine cocktail for 8 days. Insulin release
from islets was measured at day 10 by sequentially stimulating islets with Kreb’s buffer
containing 2.5 mM (basal) and 22 mM glucose (stimulated) at 37°C for 1 h.
5.2.4 Islet transplantation
Animal experiments were performed in accordance with the NIH guidelines using a
protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of Tennessee Health Science Center. Diabetes was induced by
intraperitoneal injection of low dose streptozotocin (STZ) (70mg/kg) to NSG mice for 2
consecutive days. Animals were classified as diabetic when two consecutive
measurements of blood glucose were ≥ 400mg/dl with a glucometer. Prior to receiving
human islets from the Integrated Islet Distribution Program distribution centers,
hBMSCs were transduced with Adv-hVEGF-hIL-1Ra at an MOI of 200. Islets and
hBMSCs were co-transplanted under the kidney capsules of STZ induced diabetic mice.
Three shots of insulin (5U/kg) were given to each mouse on the first 3 days after
transplantation to relieve the hyperglycemic stress to the newly-transplanted islets
(207). The non-fasted glucose levels of all the mice were measured from the snipped
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tail of each animal at 14.00 h during the first week after surgery and then weekly. At the
end of study, the mice were anaesthetized by isoflurane inhalation to collect blood to
measure human serum insulin and c-peptide levels by ELISA.
5.2.5 Intraperitoneal glucose tolerance test
Fifteen days after islet transplantation, glucose tolerance was determined in
overnight-fasted mice, which were subjected to intraperitoneal injection of glucose at 2
g/kg of body weight (208). Blood samples were obtained from the snipped tail at 15, 30,
60, 90 and 120 min after injection and analyzed for glucose levels with a glucometer.
5.2.6 Immunofluorescence staining
Mice from each group were sacrificed at the end of study and the kidneys bearing
islets were removed, washed with PBS, fixed in 4% paraformaldehyde overnight, and
embedded in optimal cutting temperature (O.C.T.). Frozen sections of 10mm thickness
were cut. To detect insulin positive human islets, the slides were stained with guinea pig
anti-human insulin primary antibody (dilution 1:200) at 4 °C overnight and Alexa Fluor
568-conjugated goat anti-guinea pig secondary antibody (dilution 1:500) at room
temperature for 1 h. To detect revascularization, the slides were stained with rabbit antihuman vWF primary antibody (dilution 1:500) at 4 °C overnight and Dylight 488conjugated goat anti-rabbit secondary antibody (dilution 1:500) at room temperature for
1 h. Slides were counter-stained with DAPI.
5.2.7 Statistical analysis
Statistical significance of the difference between the two groups was determined by
an unpaired Student’s t-test and between several groups by one-way analysis of
variance.
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5.3 Results
5.3.1 Characterization, transduction and differentiation of hBMSCs
Flow cytometric analysis showed hBMSCs were positive for cell surface markers
CD73, CD146, CD105, CD90 and Stro-1 (Figure 5.1A). Nanog, Oct4 and Sox 2 are
known pluripotency markers and their expression indicates stem cell immaturity. Real
Time RT-PCR data have shown that expression of these markers was not affected by
the adenovirus transduction suggesting that hBMSCs can be used as gene delivery
vehicles without affecting their stemness (Figure 5.1B).
Transduction

of

hBMSCs

with

Adv-hVEGF-hIL-1Ra

resulted

in

significant

overexpression of hVEGF and hIL-1Ra, which peaked at day 4 and gradually returned
to basal levels at day 10 (Figure 5.2 A & B). We observed dose and time dependent
expression of hVEGF and hIL-1Ra. Overexpression of transgenes is transient as
adenoviral vector does not result in integration of genome.
Transduction of hBMSCs with adenovirus did not affect the differentiation potential of
hBMSCs as evident from oil red staining of adipocytes from differentiated hBMSCs
(Figure 5.1C). We did observe osteogenic differentiation of transduced hBMSCs,
however it did affect osteogenic differentiation which was evident from the extent of
area of alizarin red positive cells.
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A

B

Figure 5-1.

C

Phenotypic characterization of cultured hBMSCs.

(A) Flow cytometry analysis for expression of hBMSCs surface markers. hBMSCs are
positive for CD73, CD146, CD105, CD90 and Stro1. Open peaks indicate the isotype of
each cell and solid peaks represent expression of each marker. Numbers in the box
specify the percentage of positive cells as compared to isotype control. (B) Expression
of stem cell markers after transduction of hBMSCs with Adv-hVEGF-hIL-1Ra at 200
MOI. Real Time RT-PCR analysis to quantify change in the expression of Nanog and
Oct4 stemness markers. Data are represented as the mean ± SD, n=3. (C)
Differentiation of Adv-hVEGF-hIL-1Ra transduced hBMSCs. Oil red and alizarin red S
staining of hBMSCs after culture in adipogenic and osteogenic differentiation media was
performed respectively.
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Figure 5-2.

Quantification of expression of (A) hVEGF and (B) hIL-1Ra after
transduction of hBMSCs.

Expression of (A) hVEGF and (B) hIL-1Ra measured by ELISA after transduction of
hBMSCs with Adv-hVEGF-hIL-1Ra at MOI of 100 and 200. Data are represented as the
mean ± SD, n=3.
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5.3.2 Islet viability study
PNF of islets after transplantation is the primary reason for the loss of islet function.
Inflammatory cytokine cocktail was used to simulate PNF. Prevention of PNF of islets
by hBMSCs overexpressing hIL-1Ra was measured by the membrane fluorescent
staining method. Islets upon exposure to inflammatory cytokines showed significant cell
death as evident from red PI staining in the core of islets (Figure 5.3A). We
demonstrated that overexpression of hIL-1Ra by hBMSCs prevented the islet cell death
as there are only few PI stained red cells in the islet. While hBMSCs reduced the level
of islet cell death, overexpression of hIL-1Ra could significantly reduce the islet cell
death (Figure 5.3A).
Islets alone upon culture for 10 days maintained insulin releasing function upon
stimulation with glucose (SI =1.52). Co-culture of hBMSCs alone with islets could not
prevent the islet cell death, resulting in the SI of insulin less than 1 (SI = 0.88) (Figure
5.3B). However, overexpression of hIL-1Ra by hBMSCs restored insulin release by the
islets in response to stimulatory glucose concentrations (SI=1.53). Islet viability by
membrane fluorescent staining and glucose stimulated insulin release assay have
shown that overexpression of hIL-1Ra by hBMSCs could prevent the PNF and maintain
insulin releasing function of islets to stimulatory glucose concentration.
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A

B

Figure 5-3.

Protection of islets by transduced hBMSCs against cytokines.

(A) Calcein AM and PI staining Islets, islets with hBMSCs and islets with transduced
hBMSCs with Adv-hVEGF-hIL-1Ra at the ratio of 1 islet equivalent to 100 hBMSCs. (B)
Stimulation index (SI) of human islets after incubation with inflammatory cytokine
cocktail of 5 ng/ml IL-1β, 10 ng/ml TNF-α and 50 ng/ml IFN-γ for 10 days. Nontransduced islets were used as controls. SI was determined as the ratio of insulin
released from islets when they are incubated in Kreb’s buffer containing 22mM and 2.2
mM glucose. Data are presented as the mean ± SE (n=3)
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5.3.3 Cotransplantation of hBMSCs overexpressing hVEGF and hIL-1Ra
improved islet transplantation
Transplantation of 2000 islet equivalents (IEs) was able to reverse diabetes in all the
transplanted

animals.

However,

co-transplantation

of

islets

with

hBMSCs

overexpressing hVEGF and hIL-1Ra resulted in better glycemic control in terms of the
mean blood glucose level, duration of normoglycemia and response to glucose
challenge. Islets alone could reverse diabetes only up to 21 days in most of the animals
(Figure 5.4A). Although hBMSCs improved the islet transplantation outcome, there was
still rapid increase in blood glucose level when untransduced hBMSCs were utilized. In
contrast, co-transplantation of islets with Adv-hVEGF-hIL-1Ra transduced hBMSCs
significantly increased the diabetes reversal ratio, suggesting the positive role of AdvhVEGF-hIL-1Ra transduced hBMSCs on islet transplantation (Figure 5.4D). To
determine the functional viability of islet grafts after islet transplantation, the mice were
anesthetized to collect blood to measure human serum insulin and C-peptide levels by
ELISA. The levels of human insulin and C-peptide of the mice co-transplanted with AdvhVEGF-hIL-1Ra-transduced hBMSCs were significantly higher than those of the mice
transplanted with islets alone (Figure 5.5 C&D).
This

improvement

in

islet

transplantation

was

confirmed

by

performing

intraperitoneal glucose challenge. Blood glucose levels increased immediately after
glucose (2 g/kg) injection, peaked at 15 min in all groups, and then decreased over
time. Co-transplantation of islets with transduced hBMSCs showed accelerated glucose
clearance resulting in lower blood glucose levels at 15 and 30 min post glucose injection
(Figure 5.5A). Islets transplanted with Adv-hVEGF-hIL-1Ra transduced hBMSCs had a
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better engraftment outcome and led to superior glucose control and tolerance compared
to islets or islets with hBMSCs.
5.3.4 Immunofluorescence staining
Immunofluorescence staining of the kidney section bearing transplanted islets
showed the engraftment of insulin-positive islets under the kidney capsule. vWF staining
was performed to assess the extent of vascularization of islets. vWF staining was
undetectable in the kidney sections bearing islets alone and sparse in the kidney
sections bearing islets and un-transduced primary hBMSCs (Figure 5.6 B). However,
vWF staining in the kidney sections bearing islets co-transplanted with Adv-hVEGF-hIL1Ra transduced primary hBMSCs was detected. Analysis of human insulin and vWF
immunofluorescence suggested increased revascularization of islets when cotransplanted with Adv-hVEGF-hIL-1Ra transduced primary hBMSCs (Figure 5.6 A&B).
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A

B

D

C

Figure 5-4.
Effect of Adv-hVEGF-hIL-1Ra
outcome of human islet transplantation.

transduced hBMSCs

on the

(A, B, C) The blood glucose level of every mouse after receiving 2000 human islet
equivalent transplanted either alone or hBMSCs before or after transduction with AdvhVEGF-hIL-1Ra (A-C). (D) Diabetes reversal ratio of the diabetic mice after human islet
transplantation. Blood glucose ≤ 250 mg/dl (dashed line) was identified as reverseddiabetes (dashed line in A, B, C). Black triangles indicate mice receiving islets with AdvhVEGF-hIL-1Ra transduced hBMSCs; Gray squares indicate mice receiving islets with
hBMSCs; Black diamond’s indicate mice receiving islets only.
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A

C

B

Figure 5-5.
Outcome of islet transplantation assessed by intraperitoneal
glucose tolerance test and serum levels of human insulin and C-peptide.
(A) Intraperitoneal glucose tolerance test after 15 days of islet transplantation by
measuring blood glucose level. Data are presented as the mean ± SD (n=5). (B-C)
Effect of Adv-hVEGF-hIL-1Ra transduced hBMSCs on human serum insulin and Cpeptide levels of diabetic NSG mice transplanted with either islet alone or with hBMSCs
only or with Adv-hVEGF-hIL-1Ra transduced hBMSCs at 35 days post transplantation.
Data are presented as the mean ± SD, n=5. P<0.05 under t-test.
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Figure 5-6.
Immunofluorescence staining of the kidney section for insulin
and vWF 35 days after islet transplantation.
Insulin was stained in red to indicate the functional human islets after transplantation.
vWF was stained in green to indicate the revascularization of transplanted human islets.
Kidney section of mice bearing human islets; human islets co-transplanted with
hBMSCs; human islets co-transplanted with Adv-hVEGF-hIL-1Ra transduced hBMSCs.
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5.4 Discussion
Type I diabetes is characterized by autoimmune destruction of islets and requires
lifelong administration of insulin to maintain normoglycemeia. Since the success of
Edmonton protocol, islet transplantation has been performed in many patients
especially undergoing kidney transplantation (209). However, the proportion of
recipients who achieved insulin independence is low and required supplemental
administration of insulin to achieve normoglycemeia (210).
Majority of islets undergo apoptosis within a week or two after transplantation due to
inflammatory reaction, mediated by inflammatory cytokines like IL-1β, TNF-α and IFN-
released by infiltrating immune cells (211, 212). Among various inflammatory cytokines,
IL-1β is the major inflammatory cytokine whose expression is upregulated during islet
isolation procedure, culture and upon exposure to hyperglycemic conditions (213-215).
Human islets exposed to IL-1β undergo NFkB activation, Fas upregulation and DNA
fragmentation, eventually leading to β-cell death (216, 217). To prevent IL-1β induced βcell apoptosis, human islets have been genetically modified to overexpress hIL-1Ra
locally

(196).

Our

group

has

also

demonstrated

that

adenovirus

mediated

overexpression of hIL-1Ra can block IL-1β induced caspase activation, impaired
glucose stimulated insulin release, and Fas triggered apoptosis (7, 206).
hBMSCs are heterogeneous population of cells and differ in clonogenicity,
proliferation capacity and differentiation potential (218, 219). The International Society
for Cell Therapy (ISCT) has proposed expression of cell surface markers CD73, CD90
and CD105 as minimum criteria to characterize hBMSCs (220). Stro-1 is a marker of
early mesenchymal stromal precursor cells and strongly linked to hBMSCs colony
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forming efficiency, plasticity and other paracrine signaling (221, 222). Level of
expression of CD146 has been shown to correlate with the proliferation capacity of
MSCs and their differentiation potential (220). Our flow cytometry data (Figure 5.1A)
have shown that hBMSCs used in this study adhere to the minimum criteria set by ISCT
and have high proliferation potential as evident by Stro-1 and CD146 expression.
hBMSCs can be readily transduced with all the known viral vectors and efficiently
overexpress transgene (223, 224). Ease of isolation, absence of immuno co-stimulatory
receptors, their immunomodulatory and anti-inflammatory properties make hBMSCs an
ideal gene delivery vehicle (225). It is imperative to demonstrate that genetic
modification of hBMSCs do not affect their differentiation potential, stemness,
immunological properties and secretion of paracrine factors. Adipogenic differentiation
of transduced hBMSCs as confirmed by Oil Red staining demonstrated that ex vivo
modification of hBMSCs with adenovirus did not alter their differentiation potential
(Figure 5.1C). However, we did observe reduction in the extent of osteogenic
differentiation of transduced hBMSCs. This reduction in osteogenic differentiation of
transduced hBMSCs could be attributed to paracrine effects of accumulated hVEGF
and hIL-1Ra in the differentiation media. These results are different from previously
published reports that genetic modification of MSCs did not affect their differentiation
potential (226) and requires consideration of the effect of accumulated paracrine factors
on the differentiation of genetically modified hBMSCs. Tracy et al have also shown that
adenovirus transduction of BMSCs did not adversely affect their immunological
properties as well as expression of chemokines and chemokine receptors (227).
However, they did not determine the effect of genetic modification on stemness as
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measured by expression of Nanog and Oct4 genes which are the key transcription
factors for maintaining pluripotency and self-renewal potential of undifferentiated
embryonic stem cells (228). Forced expression of Nanog or Sox2 maintained the
expansion and differentiation potential of MSCs (229). Here we have shown that
adenovirus modification of hBMSCs did not alter the expression of Nanog and Oct4
(Figure 5.1B). In addition, previously we have shown that transduction of hBMSCs did
not alter their paracrine secretions (230). Our results indicate that adenoviral
modification of hBMSCs do not alter their proliferation, differentiation potential,
expression of surface markers, immunological properties, stemness, and therefore
hBMSCs have the potential to be used as gene delivery vehicles.
MSCs as cell therapy has demonstrated efficacy both in the treatment of type 1
diabetes and islet transplantation (231-234). There are conflicting reports whether
hBMSCs undergo transdifferentiation to insulin secreting β cells or hBMSCs prevent
islet apoptosis through the secretion of growth factors.

Ito et al. have shown that

secretion of VEGF by BMSCs improved islet revascularization and thereby islet
transplantation (233). hBMSCs secrete an array of angiogenesis growth factors which
promote islet vascularization and islet growth (235). However, basal secretion of VEGF
(Figure 5.2A) and other growth factors by hBMSCs is not enough to support the
revascularization of islet graft soon after transplantation. Similarly, secretion of IL-1Ra
by MSCs alone could not abrogate IL-1β mediated inflammation. Therefore, lentiviral
modification of MSCs to overexpress IL-1Ra has been performed to enhance their antiinflammatory potential (236).
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In this study, we have shown that hBMSCs can be genetically modified with
bicistronic adenoviral vector to promote islet revascularization and prevent islet
apoptosis. Considering the safety, transduction efficiency and duration of transgene
expression, adenovirus was preferred over retrovirus and plasmid DNA. Ex vivo genetic
modification of hBMSCs resulted in significant co-expression of hVEGF and hIL-1Ra
(Figure 5.2 A & B). This pattern of transgene expression is desirable as islet apoptosis
occurs immediately after transplantation. hBMSCs and islets can be either co-cultured
together or separated through a cell culture insert. We have co-cultured islet and
hBMSCs together as reported previously by Duprez et. al (237). Genetically modified
hBMSCs co-cultured with islets protected islets against inflammatory cytokines and
improve the islet viability as evident from Calcein AM/PI staining (Figure 5.3A).
To determine whether co-transplantation of human islets with Adv-hVEGF-hIL-1Ra
transduced hBMSCs can improve the outcome of islet transplantation, mean blood
glucose levels were measured in NSG diabetic mouse model after transplantation of
islets alone or with hBMSCs or with Adv-hVEGF-hIL-1Ra transduced hBMSCs (Figure
5.4). Co-transplantation of Adv-hVEGF-hIL-1Ra transduced hBMSCs significantly
improved diabetic reversal ratio and response to intra peritoneal glucose challenge
(Figure 5.4 & 5.5A). hvWF factor staining as marker of endothelial cell proliferation was
more evident

in Adv-hVEGF-hIL-1Ra transduced hBMSCs (Figure 5.6). Prominent

green staining in Adv-hVEGF-hIL-1Ra transduced hBMSCs indicates that expression of
hVEGF enhanced the endothelial cell proliferation of transplanted islet. To correlate the
advantage of islet revascularization with the islet mass in the kidney capsule, we also
stained for human insulin. Co transplantation of islet with Adv-hVEGF-hIL-1Ra
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transduced hBMSCs displayed significantly higher levels of insulin content than
untransduced hBMSCs or islet alone (Figure 5.6). These findings correlated well with
serum human insulin and C-peptide levels (Figure 5.5 B&C) and immunofluorescent
staining (Figure 5.6). In conclusion, our results have demonstrated that hBMSCs can be
used as gene delivery vehicles without affecting their stemness and differentiation
potential. Over expression of VEGF and IL-1Ra protected islet viability, promoted
revascularization and significantly improved the glycemic control in diabetic mice model.
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Chapter 6 SUMMARY AND FUTURE RESEARCH
6.1 Summary
Melanoma originated from malignant transformation of melanocytes is highly
aggressive cancer with multi drug resistance and poor prognosis. Melanocytes
proliferate upon exposure to UV radiation and this tendency of melanocytes to survive
and proliferate under stress programs them to survive. Additionally, the mutation of
oncogene and tumor suppressors which include BRAF, NRAS, Kit and so on drives the
process of melanomagenesis. Despite the improvement in survival with the recent
advances in targeted therapy (e.g. BRAF inhibitors vemurafenib and dabrafenib; MEK
inhibitor trametinib), acquired drug resistance often develops within a few months and
the overall survival for malignant melanoma remains low. Therefore, there is an urgent
need to develop more effective treatment modalities for treating malignant melanoma.
This dissertation is focused on developing and investigating nanocarriers based delivery
of photodynamic agent and tubulin binding agents for treatment of melanoma.
Tumor specific localization of photosensitizer and deep tissue penetration of light is
essential for application of phototherapy. ICG with absorption in the NIR range with
excellent safety profile is a suitable candidate for phototherapy but its clinical potential
for phototherapy is limited by short half-life and inefficient tumor accumulation. To
improve biodistribution and efficacy of ICG based phototherapy, we designed polymeric
micelles of ICG. Amino derivative of ICG was synthesized and characterized for its
conjugation to polymeric backbone and its formulation as micelles.

Amphiphillic

copolymer, poly (ethylene glycol)-block-poly(2- methyl-2-carboxyl-propylene carbonate)
(PEG-PCC) with pendant carboxyl group was synthesized for conjugation of amino ICG.
Polymeric micelles formulated from ICG polymer conjugate exhibited mean particle size
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of 30-50 nm size and drug loading of 10.2%. Micellar formulation demonstrated
significant in vitro photothernal cytotoxicity upon irradiation at 800 nm. Unlike micelles,
ICG solution exhibited photodynamic toxicity which can be reversed by sodium azide.
This contrasting mechanism of cytotoxicity of ICG micelles and ICG solution was
elucidated by poor cellular uptake of ICG micelles. ICG conjugated micelles prolonged
its circulation and increased tumor accumulation through enhanced permeability and
retention effect resulting in complete tumor regression upon irradiation of ICG
conjugated micelles compared to free ICG and control in a A375 human melanoma
tumor model in athymic nude mice. In vivo NIR fluorescence imaging and efficacy data
showed that we were able to design ICG conjugated micelles with excellent in vivo
stability which resulted in prolonged plasma circulation and enhanced tumor
accumulation with significant efficacy in melanoma.
LY293, a 5 indole derivative tubulin binding agent was synthesized with nanomolar
efficacy to overcome Pgp mediated drug resistance. However, poor aqueous solubility
of LY293 warranted use of toxic cosolvents for its systemic therapy. Biodegradable
polymer with polyester and polycarbonate hydrophobic core was synthesized for
systemic therapy of nanoparticulate formulation of LY293. Methoxy polyethylene glycolb-poly

(carbonate-co-lactide)

(mPEG-b-P

synthesized and characterized by

(CB-co-LA))

random

copolymer

was

1

H NMR and GPC. Polymeric nanoparticles

formulated using o/w emulsification method had appreciable LY293 loading with no loss
of in vitro cytotoxicity as compared to free drug. In vivo, systemic administration of
LY293 loaded nanoparticles significantly inhibited the proliferation of metastatic
melanoma in syngeneic lung metastasis melanoma mouse model.

118

Primary non-function of islets and graft rejections remains key obstacles for
successful human islet transplantation. We utilized hBMSCs as a novel gene carrier to
express two therapeutic genes while avoiding the viral transduction on human islets.
hBMSCs transduced with bicistronic adenoviral vectors encoding VEGF and IL-1Ra
overexpressed these transgenes to promote revascularization of islets and protect the
islets from immune mediated destruction. Genetically modified hBMSCs protected
viability of islets against cytokine cocktail as confirmed by live/dead staining. Upon
cotransplantation of islets with transduced hBMSCs demonstrated better glycemic
control as compared to mice transplanted with islets alone or islets cotransplanted
hBMSCs. There was also an associated increase in the serum levels of insulin and cpeptide which was supported by immunofluorescent staining of kidney sections for
insulin and human von Willebrand factor (marker for endothelial cells) in islets
cotransplanted with genetically modified hBMSCs group. In conclusion, our results
demonstrate that hBMSCs may be used as gene carriers and nursing cells to improve
the outcome of islet transplantation.
6.2 Future Directions
The findings presented in this thesis demonstrated proof of principle that micelles
formulation of ICG improved its plasma circulation and tumor accumulation through
EPR effect. Cell uptake and cytotoxicity mechanistic studies demonstrated that polymer
conjugated ICG micelles formulation have poor cellular uptake. To improve the cellular
uptake of ICG micelles, we would like to explore physical encapsulation as well as
conjugation of ICG to the polymeric backbone by tumor overexpressed protease
selective peptide (238-240). Moreover, photodynamic property of ICG can also be
utilized for photochemical internilzation (155). Reactive oxygen species generated by
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photodynamic therapy led to rupture of endosomal membrane and cytosolic release of
endosomes entrapped drugs and macromolecules. We would like to evaluate
combination of photodynamic therapy and chemotherapeutic agent for the treatment of
melanoma (241, 242).
In chapter 4, we have demonstrated that LY293, tubulin inhibitor showed excellent
efficacy in lung metastasis melanoma model. However, there was lack of significant
difference between nanoparticulate formulation and cosolvent solution of LY293 which
may be due to premature release of the encapsulated drug from the nanoparticle core.
We would like to perform pharmacokinetic and biodistribution to study difference in
plasma profile of nanoparticulate formulation and cosolvent solution. In addition, we
would also like to explore alternative nanoparticulate formulation approaches to
minimize the premature LY293 release from nanoparticles and further improve the
tumor accumulation. Polymeric drug conjugates have been shown to be stable in the
circulation resulting in enhanced tumor accumulation. For future studies, we plan to
redesign the polymeric nanocarriers as well as synthesize drug analogs with function
groups for chemical conjugation which will allow preferential tumor accumulation and
reduction of peripheral toxicity on systemic administration.
We demonstrated use of human bone marrow derived mesenchymal stem cells as
gene delivery vehicles. Genetically modified hBMSCs improved islet viability against
inflammatory cytokines and promoted revascularization of transplanted grafts.
However, the level of expression of transgene was significantly lower as compared to
genetic modification of islets which can be attributed to low expression of coxsackievirus
and adenovirus receptor (CAR) by hBMSCs (243). To improve the transduction
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efficiency and increase the transgene expression, we would like to use cationic
polymers, peptides or modify the surface of adenovirus for targeting receptors
expressed by hBMSCs (244-246). hBMSCs have strong immunosuppressive effect and
tropic effect. Further studies evaluating the immunosuppressive effect of genetically
modified stem cells will be evaluated in humanized mouse model. Evaluation of efficacy
of contransplantation islet with genetically modified hBMSCs in humanized mouse
model could be a perfect model and use of humanized mouse model is warranted to
assess the islet transplantation in preclinical models.
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